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The objective of the study was to characterize the toxicity from sub-chronic inhalation of test atmo-
spheres from the candidate modiﬁed risk tobacco product (MRTP), Tobacco Heating System version 2.2
(THS2.2), and to compare it with that of the 3R4F reference cigarette. A 90-day nose-only inhalation
study on Sprague-Dawley rats was performed, combining classical and systems toxicology approaches.
Reduction in respiratory minute volume, degree of lung inﬂammation, and histopathological ﬁndings in
the respiratory tract organs were signiﬁcantly less pronounced in THS2.2-exposed groups compared with
3R4F-exposed groups. Transcriptomics data obtained from nasal epithelium and lung parenchyma
showed concentration-dependent differential gene expression following 3R4F exposure that was less
pronounced in the THS2.2-exposed groups. Molecular network analysis showed that inﬂammatory
processes were the most affected by 3R4F, while the extent of THS2.2 impact was much lower. Most
other toxicological endpoints evaluated did not show exposure-related effects. Where ﬁndings were
observed, the effects were similar in 3R4F- and THS2.2-exposed animals. In summary, toxicological
changes observed in the respiratory tract organs of THS2.2 aerosol-exposed rats were much less pro-
nounced than in 3R4F-exposed rats while other toxicological endpoints either showed no exposure-
related effects or were comparable to what was observed in the 3R4F-exposed rats.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The U.S. Family Smoking Prevention and Tobacco Control Act
(FSPTCA) deﬁnes a MRTP as “any tobacco product that is sold or
distributed for use to reduce harm or the risk of tobacco related
disease associated with commercially marketed tobacco products”
(Family Smoking Prevention and Tobacco Control Act). This(P. Vanscheeuwijck).
s.
r Inc. This is an open access articlepublication is part of a series of nine publications describing the
nonclinical and part of the clinical assessment of a candidate MRTP,
THS2.2 regular and a mentholated version (THS2.2M). The series of
publications provides part of the overall scientiﬁc program to
assess the potential for THS2.2 to be a reduced risk product. The
ﬁrst publication in this series describes THS2.2 and the assessment
program for MRTPs (Smith et al., submitted (this issue)). This is
followed by six publications, including this one, that describe the
nonclinical assessment of THS2.2 regular and THS2.2M (Kogel et al.,
submitted (this issue); Oviedo et al., submitted (this issue); Schaller
et al., submitted (this issue)-a; Schaller et al., submitted (this issue)-
b; Sewer et al., submitted (this issue); Wong et al., submitted (this
issue)). The eighth publication in the series describes a clinicalunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
Abbreviations
THS2.2 Tobacco Heating System version 2.2
HPHCs Harmful and potentially harmful components
MRTP Modiﬁed risk tobacco product
OECD Organization for Economic Co-operation and
Development
CO Carbon monoxide
MA Mainstream aerosol
MS Mainstream smoke
GLP Good Laboratory Practice
AAALAC American Association for the Accreditation of
Laboratory Animal Care
AVA Agri-Food & Veterinary Authority of Singapore
PMI Philip Morris International
PDSP Programmable Dual-port Syringe Pump
COHb Carboxyhemoglobin
HOCOT Trans-3’-hydroxycotinine
NCOT Norcotinine
COT Cotinine
NNO Nicotine-N’-oxide
NNIC Nornicotine
HPLC High-performance liquid chromatography
ABF Analytisch-biologisches Forschungslabor GmbH
HPMA 3-hydroxypropylmercapturic acid
NNAL 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol
SPMA S-phenylmercapturic acid
CEMA 2-cyanoethylmercapturic acid
LC-MS Liquid chromatography-tandem mass spectrometry
PT Prothrombin time
APTT Activated partial thromboplastin time
BALF Bronchoalveolar lavage ﬂuid
PBS Phosphate-buffered saline
MyriadRBM Myriad Rules-Based Medicine
EGAFS Ethanol glycerol acetic acid formaldehyde saline
H&E Hematoxylin andeosin
AB-PAS Alcian blue/periodic acid-Schiff's reagent
LPT Laboratory of Pharmacology and Toxicology GmbH &
Co. KG
HBSS Hepes-buffered saline solution
TPM Total particulate matter
RNE Respiratory nasal epithelium
fRMA Frozen-Robust Microarray Analysis
FDR False discovery rate
RBC Red blood cells/erythrocytes
Hb Hemoglobin concentration
MCV Mean corpuscular volume
MCHC Mean cell hemoglobin content
MCH Mean corpuscular hemoglobin
HCT Hematocrit
ALP Alkaline phosphatase
AST Aspartate aminotransferase
ALT Alanine aminotransferase
MMAD Mass median aerodynamic diameter
GSD Geometric standard deviation
LOQ Lower limit of quantiﬁcation
PIF Peak inspiratory ﬂow
TV Tidal volume
RF Respiratory frequency
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Potentially Harmful Constituents (HPHCs) for THS2.2 regular also
leads to reduced exposure to HPHCs when the product is used in a
clinical setting (Haziza, submitted (this issue)). A ﬁnal publication
utilizes data gathered from the reduced exposure clinical study on
THS2.2 regular to determine if a systems pharmacology approach
can identify exposure response markers in peripheral blood of
smokers switching to THS2.2 (Martin et al., submitted (this issue)).
Here we report the results of a 90-day inhalation study that was
conducted to identify and characterize potentially adverse toxico-
logical effects and underlining molecular changes following
repeated daily inhalation exposure to test atmosphere from THS2.2
and 3R4F in Sprague Dawley rats. The recommendations from the
Organization for Economic Co-operation and Development (OECD)
Test Guideline 413 (OECD, 2009) were followed during the
conceptualization and the conduct of this study, with special
emphasis on histopathology of the respiratory tract, lung inﬂam-
mation, and additional molecular endpoints using transcriptomics
analysise the latter being a part of a systems toxicology assessment
to enable a multi-level systems evaluation of the effects of aerosol
inhalation, and to provide insights into the mechanistic drivers
behind the changes observed (Kogel et al., submitted (this issue)).2. Materials and methods
2.1. Experimental design
Ninety two male and 92 female Sprague Dawley rats were
allocated into 7 groups (named the ‘OECD groups’). Rats were
exposed to ﬁltered fresh air (sham), diluted mainstream aerosol(MA) from THS2.2 at 3 target concentrations of nicotine (15, 23 and
50 mg nicotine/l aerosol, designated as THS2.2_15, THS2.2_23, and
THS2.2_50), or diluted mainstream smoke (MS) from 3R4F at 3
target test atmosphere concentrations of nicotine (8, 15 and 23 mg
nicotine/l aerosol, designated as 3R4F_8, 3R4F_15, and 3R4F_23).
Groups of 10 male and 10 female rats were exposed for a period of
90e96 days (90d) at an exposure regimen of 6 h a day, 5 days per
week (no exposure on weekend), and were subsequently eutha-
nized and necropsied. Additional cohorts of 6e10 rats per sex,
concomitantly exposed with the 90-day animals, were kept for
approximately additional 42 days (90 þ 42d) to assess reversibility
or persistence of ﬁndings, and consisted of a sham, a 3R4F_23
group, and a THS2.2_50 group, named ‘recovery groups’. These rats
were euthanized and necropsied 44e45 days after the completion
of the 90-day exposure period (Supplementary Table 1). In addition
to the OECD groups, Sprague Dawley rats were also allocated to 7
‘OECD Plus’ groups, and exposed to the same aerosols in the same
inhalation chambers, concomitantly with the OECD groups. In the
OECD Plus groups, 6 male and 6 female rats per group were allo-
cated for 90d (actual 93e96 days) exposure, and 5 to 6 rats per sex
per group (with the exception of the THS2.2_50 group) were allo-
cated for 90 þ 42d exposure (actual 42e44 days) (Supplementary
Table 1).
The nicotine concentrations for 3R4F were selected according to
results from a previous study (Kogel et al., 2014), which showed
that the selected concentrations were suitable for detecting dif-
ferences in severity of effects throughout the respiratory tract
without causing signiﬁcant increase in morbidity due to high car-
bon monoxide (CO) concentration in the aerosol. The highest test
atmosphere nicotine concentration that was selected for the
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ﬁndings from a concentration range-ﬁnding study conducted prior
to the study reported here (results not shown), which showed that
this nicotine concentration caused mild toxicity but not an increase
in morbidity. Exposing rats to MS from 3R4F at such high test at-
mosphere nicotine concentrations would not be possible because
of the CO content in 3R4F smoke. THS2.2 aerosol contains much
lower levels of CO and other constituents (see Schaller et al., 2016),
allowing test atmospheres up to 50 mg nicotine/l. Consequently, the
target nicotine concentration of the 3R4F_23 groupwasmatched to
that of the THS2.2_23 group, and the target nicotine concentration
of the 3R4F_15 group was matched to that of the THS2.2_15 group.
The test atmospheres were characterized by measuring selected
aerosol constituents throughout the study. Data were collected for
clinical observations, aerosol uptake (biomonitoring), clinical pa-
thology, gross pathology, organ weights, and histopathology ac-
cording to the OECD 413 speciﬁcations. Supplementary Table 3
summarizes all OECD and molecular endpoints (OECD Plus
groups) collected in this study. The exposure part of the study, as
well as the determination of all OECD endpoints, was conducted in
compliance with the OECD Principles on Good Laboratory Practice
(GLP) (OECD, 1997), with the exception of bronchoalveolar lavage
ﬂuid (BALF) analytics using RodentMAP®, determination of bio-
markers of exposure for acrolein, (4-Methylnitrosamino)-1-(3-
Pyridyl)-1-butanone (NNK), benzene, acrylonitrile, and the
exploratory transcriptomics/miRNA investigations.
2.2. THS2.2 tobacco sticks and cigarettes
THS2.2 is a heat-not-burn tobacco product, consisting of an
electrically operated chargeable heating element (stick holder) and
THS2.2 tobacco stick containing a tobacco plug. THS2.2 tobacco stick
consist of a tobacco plug made out of specially processed recon-
stituted tobacco (cast leaf), a transfer section, and a mouthpiece,
with an over-wrapping of cigarette paper. THS2.2 tobacco sticks are
designed to be inserted into the stick holder that includes a battery,
electronics for heat control, a heating element (blade), and the
cigarette extractor. The heating element of the holder heats the
tobacco plug in a temperature-controlled manner to a maximum of
350 C. The comparative analytical characteristics of THS2.2 aerosol
and 3R4F smoke are reported in part 2 of this series of publications
(Schaller et al., submitted (this issue)-a). The tobacco blend desig-
nated ‘FR1’ was used in the THS2.2 tobacco sticks in this study. The
tobacco sticks were provided by Philip Morris Products S.A., Neu-
cha^tel, Switzerland.
Reference research cigarettes 3R4F were purchased from the
University of Kentucky (http://www2.ca.uky.edu/refcig/). The 3R4F
reference cigarette is constructed to represent the “full ﬂavor”
segment of the American market. Detailed 3R4F smoke analytics
can be found in Roemer et al., (Roemer et al., 2012).
2.3. Animals
All procedures involving animals were performed in an AAALAC
(American Association for the Accreditation of Laboratory Animal
Care) accredited, AVA (Agri-Food & Veterinary Authority of
Singapore) licensed facility with approval from an Institutional
Animal Care and Use Committee, and performed in compliance
with guidelines set by the National Advisory Committee for Labo-
ratory Animal Research (NACLAR, 2004).
Outbred male and female Sprague Dawley rats (Crl:CD(SD)),
bred under speciﬁc pathogen-free conditions, were obtained from
Charles River, USA (breeding area Raleigh R04). Sprague Dawley
rats were selected because of the extensive experience with this
strain in previous inhalation studies conducted by Philip MorrisInternational (PMI) and extensive published literature (Kogel et al.,
2014; Moennikes et al., 2008; Phillips et al., 2015a; Terpstra et al.,
2003; Vanscheeuwijck et al., 2002). The rats were approximately
8 weeks old at arrival and were acclimatized for 17 days for OECD
groups and 24 days for OECD Plus groups prior to exposure
(exposure of OECD Plus groups commenced 1 week after the OECD
group). Serological testing was performed on 6 male and 6 female
sentinel rats in week 10 of the study. Additional sentinel animals
were sent for comprehensive microbiological, serological and his-
topathological evaluation at Envigo, UK: 6 live male and 6 live fe-
male rats before exposure, 2 live male and 2 live female rats on
week 13, and 4 live male and 4 live female rats after week 19. Only
Staphylococcus species, Streptococcus species, Proteus species,
Lactobacillus species, and Escherichia coli that were considered
normal ﬂora in rats were detected in the cecum and/or
nasopharynx.
The rats were housed in animal laboratory units with restricted
access and under speciﬁc hygienic conditions. Frequent bacterio-
logical testing performed on the laboratory air and surfaces, diet
and drinking water during the course of the study showed micro-
bial counts that were within internal speciﬁcations. The laboratory
air was ﬁltered fresh air, and positive pressure was maintained
inside the laboratories. The housing temperature for the 2 animal
housing rooms used was 21.0 ± 0.2 and 21.8 ± 0.4 C (mean ± SD),
and the relative humidity was 59.1± 1.0% and 51.6± 1.5%
(mean ± S.D.), both conditions were within the speciﬁcations
(22 ± 3 C and 30e70%). The light/dark cycle was 12 h/12 h, with
the light period beginning at 7 am.
All rats were individually identiﬁed by subcutaneously
implanted transponders. The rats were housed in pairs throughout
the exposure period with the exception of rare cases where the
group size was odd (i.e., after a death or dissection), in which some
rats were housed singly. The bedding material (Lignocel® BK 8e15,
J. Rettenmaier & Sohne, GmbH þ Co KG.) was composed of auto-
claved softwood granulate. A gamma-irradiated pellet diet (T2914C
irradiated rodent diet, Harlan) was provided on the cage top from
cage lids, and tap water (ﬁltered 0.45 and 0.2 mmpore size in series)
from water bottles with steam-sterilized sipper tubes were sup-
plied ad libitum for each cage except during exposure. Chemical
analysis of food, water and bedding material conﬁrmed that no
contaminants were present that could adversely affect the out-
comes of the study or hinder the interpretation of the data (such as
aﬂatoxins, selected pesticides, heavy metals, and polychlorinated
biphenyls; diet was also analyzed for nitrate, nitrite, nitrosamines,
and organophosphates). A total of 209 male and 179 nulliparous
and non-pregnant female rats were randomly allocated based on
sex and body weight simultaneously to 10 OECD groups and 7
OECD Plus groups by an animal management software, Provantis
(Instem, UK). The mean body weight of the rats at the beginning of
the exposure period was similar in all exposure groups, and ranged
from 284.8 to 286.2 g for male rats and 212.8e213.6 g for female
rats, with a maximum relative standard deviation of 4.3% in male
rats and 5.2% in female rats.
2.4. Aerosol generation and exposure
Both test and reference items were stored in the original pack-
aging in a room with controlled room temperature of 2e10 C, but
uncontrolled humidity. Conditioning of reference and test articles
was performed according to ISO standard 3402 (ISO3402, 1999) for
7e21 days to achieve a temperature of 22 ± 1 C and relative hu-
midity of 60 ± 3% before being used for aerosol generation.
MS from 3R4F was generated on 30-port rotary smoking ma-
chines (15 ports blocked) equippedwith a Programmable Dual-port
Syringe Pump (PDSP) with active side stream exhaust (type PMRL-
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by Philip Morris Products S.A. and manufactured by Burghart
Messtechnik, Weidel, Germany (http://www.burghart-mt.de/). MA
from THS2.2 was generated using 30-port carousel smoking ma-
chines equipped with stick holders, a PDSP, and a temperature-
controlled insulation kit (Tube Warming System) in the undiluted
aerosol pathway, to reduce aerosol condensation prior to diluting
the aerosol. The 3R4F cigarette MS and THS2.2 aerosol were
generated according to the Health Canada Intensive Smoking Pro-
tocol (Health Canada, 1999), which is based on ISO standard 3308
(ISO3308, 2000), with the exceptions of the puff volume (55 ml),
puff duration (2 s), puff frequency (one puff every 30 s), and closed
ventilation holes. Several minor deviations from ISO standard 3308
were necessary for technical reasons (see Supplementary Table 4).
The aerosols generated were diluted with ﬁltered, conditioned air
to obtain the target nicotine exposure concentrations.
The rats were individually nose-only exposed in ﬂow-pass
inhalation chambers of the type FPC-232 and in glass tubes
matching their body size. The position of the rats in the chamber
was changed on a daily basis according to a predetermined rotation
scheme. To allow for acclimatization to the target aerosol concen-
trations, a time-adaptation phase was included in week 1 of the
study during which animals were exposed 1.5 h during the ﬁrst and
second day, 3 h during the third and fourth day, and 4.5 h on days
5e7 at the target nicotine concentration. From day 8 onwards, rats
were exposed for 6 h per day. Sham rats were exposed to ﬁltered
and conditioned fresh air, the exposure conditions being the same
as those for the smoke-exposed rats. The relative humidity in the
sham exposure chamber was 55± 1% (mean ± S.D.), and the tem-
perature within the exposure chambers ranged from 21.7 to 22.4 C
(S.D. < 0.3 C). Both conditions were in compliance with those
speciﬁed by OECD TG 413 (OECD, 2009).
2.5. Analytical characterization of the test atmosphere
To characterize the test atmosphere and to check the repro-
ducibility of aerosol generation and dilution, several analytical
parameters were measured at the breathing zone of the rats in the
inhalation chambers according to previously described analytical
methods (Haussmann et al., 1998): Total particulate matter (TPM),
CO, nicotine, formaldehyde, acetaldehyde, acrolein, and particle
size distribution (PSD). For details of the frequency and methods of
determination, see Supplementary Table 5.
2.6. Biological parameters
2.6.1. General conditions and health
Body weights, food consumption, ophthalmoscopy, and health
status of the rats were monitored throughout the study
(Supplementary Table 6). Individual body weight and group food
consumption were determined at least once per week. Rats were
checked at least once each day for mortality and morbidity.
Detailed checks of the general condition and behavior of individual
rats were performed at least 4 times during the 90-day exposure
period, shortly after completion of the daily exposure. Ophthal-
mological examinations by indirect ophthalmoscopy were per-
formed on all OECD group rats before the start of the 90-day
exposure period, once during exposure, and once during the 42-day
recovery period.
2.6.2. Biomonitoring
To monitor aerosol uptake by the rats, biomonitoring was per-
formed through analysis of biomarkers of exposure for particulate
and gas vapor phase constituents, such as steady-state blood car-
boxyhemoglobin (COHb) concentration and urinary metabolites ofrepresentative aerosol constituents. In addition, respiratory physi-
ology measurements were performed. For detailed schedules, see
Supplementary Table 7.
Determination of carboxyhemoglobin in blood
Once during the 90-day exposure period and once during the
42-day recovery period, blood was collected from the saphenous
vein of isoﬂurane-anesthetized rats; levels of COHb were deter-
mined by spectrophotometric measurement of absorbance at
several wavelengths of themixed hemoglobins in hemolysate using
the NPT 7 blood gas analyzer (Radiometer, Denmark).
Urine nicotine metabolites and biomarkers of exposure
Nicotine metabolites (trans-30-hydroxycotinine (HOCOT), nor-
cotinine (NCOT), cotinine (COT), nicotine-N’-oxide (NNO), norni-
cotine (NNIC)) were determined by high-performance liquid
chromatography (HPLC) after derivatization with 1,3-diethyl-2-
thiobarbituric acid as previously described (Rustemeier et al.,
1993) in 24-h urine that was collected once before the 90-day
exposure phase started (baseline), three times during the inhala-
tion period, and once during the 42-day recovery period. The same
samples were submitted to Analytisch-biologisches For-
schungslabor GmbH (ABF, Germany) to quantify other metabolites
of aerosols constituents: 3-hydroxypropylmercapturic acid (HPMA,
metabolite of acrolein), 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol (NNAL, metabolite of NNK), S-phenylmercapturic acid
(SPMA, metabolite of benzene), and 2-cyanoethylmercapturic acid
(CEMA, metabolite of acrylonitrile). For these determinations,
liquid chromatography-tandem mass spectrometry (LC-MS)/MS
based methods were used as previously described (Mascher et al.,
2001; Meger et al., 2000; Minet et al., 2011; Scherer et al., 2007).
For a detailed schedule of the sample collection, see Supplementary
Table 7.
Respiratory physiology
Respiratory frequency, tidal volume, peak inspiratory ﬂow, and
respiratory minute volume were determined once in the study for
10 male and 10 female animals per OECD group using head-out
plethysmography (EMKA Technologies, France) to provide an esti-
mate of the irritant potential of the test atmospheres. Brieﬂy, ani-
mals were placed in modiﬁed plethysmograph exposure restraint
tubes with a latex cuff ﬁtted over the neck. After a period of accli-
matization to the plethysmograph of approximately 30 min, the
breathing patterns of the animals were recorded in 10 30-s mea-
surements. The plethysmograph was attached to the pressure
transducers that acquired the air ﬂow and air pressure signals. The
signals from the transducers were ampliﬁed by the bridge ampli-
ﬁers, and data acquisition was performed using the IOX 2.9.4.32
software package (EMKA Technologies, France).
2.6.3. Hematology and clinical chemistry
Several parameters to assess systemic effects were investigated:
Hematology and clinical chemistry were performed according to
standard laboratory methods, as previously described (Phillips
et al., 2015a). At necropsy, blood samples were taken from rats
under pentobarbital anesthesia from the retro-orbital venous
plexus, and analyzed using the Sysmex XT2000i system (Sysmex
Canada Inc., Canada); plasma samples in citrated tubes were
analyzed for prothrombin time (PT) and activated partial throm-
boplastin time (APTT) using the STA Compact coagulation analyzer
(Stago, USA). For assessment of clinical chemistry in serum, blood
samples were taken from rats at dissection under pentobarbital
anesthesia by exsanguination via the abdominal aorta, and
analyzed using the UniCel DxC 600i system (Beckman Coulter,
USA). In some instances, sample analysis was not possible or data
had to be suppressed because of insufﬁcient volume, blood clotting,
or other technical reasons. Please refer to the Results section for
actual group sizes.
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Bronchoalveolar lavage ﬂuid (BALF) was collected from the right
lungs during dissection using ﬁve consecutive cycles of instillation
at 15 cm H2O pressure and ﬂuid drawn out of the lung by gravity
and pressure from the ﬁlled lung. For the ﬁrst cycle, pre-warmed
calcium- and magnesium-free phosphate-buffered saline (PBS)
was used. For cycles 2e5, bovine serum albumin (BSA, 0.325% ﬁnal)
was added to the PBS. The lavage ﬂuid of the ﬁrst cycle was
collected separately, centrifuged, and the supernatant was used for
Luminex-based analysis of a panel of 60 selected proteins
(RodentMAP®v3.0; Life Technologies, USA) performed by Myriad
Rules-Based Medicine (Myriad RBM, USA). Cell pellets obtained
from the ﬁrst lavage cycle were re-suspended in ice cold PBS/BSA
and pooled into the BALF from cycles 2e5. The number and viability
of the free lung cells were determined, and they were further
analyzed by ﬂow cytometry (FACSCanto II, BD Biosciences, USA) to
differentiate alveolar macrophages, neutrophils, lymphocytes, and
eosinophils after staining with cell-type speciﬁc antibodies
(Supplementary Table 8)(Friedrichs et al., 2006).2.6.5. Necropsy, gross pathology and organ weights
Full necropsy was performed without prior fasting the day after
the last exposure, according to previously described methods
(Vanscheeuwijck et al., 2002). The weights of the spleen, thymus,
lung with larynx and trachea, heart, kidneys, adrenal glands, testes,
brain, and liver were determined. Organs were weighed separately
for paired organs.2.6.6. Histopathology
At the dissection time points, gross pathology was performed
and the organs listed in OECD TG 413 (see Supplementary Table 9,
pathology section) were harvested, followed by placement in
appropriate ﬁxative solutions at room temperature. The non-
respiratory tract organs were ﬁxed in a 4% formaldehyde solution
except for the eyes, sternum, and testes, which were ﬁxed in
Davidson's, Schaffer and Bouin solutions, respectively. Lungs with
larynx and trachea were removed together. After determination of
weight, the right lung was separated for BALF collection. The left
lung was ﬁxed by instillation at 20 cm H2O pressure via the left
bronchus with ethanol glycerol acetic acid formaldehyde saline
(EGAFS) and subsequent immersion. Histological sections of the
respiratory tract organs were prepared at deﬁned levels
(Supplementary Table 9), and stained with hematoxylin and eosin
(H&E). In addition, to allow for the identiﬁcation of goblet cells,
sections fromnose at level 1, trachea at level 4 (bifurcation), and left
lung at level 1 were stained with alcian blue/periodic acid-Schiff's
reagent (AB-PAS) and evaluated. The laryngeal epithelial thickness
was determined at the ﬂoor of the larynx and at the lower medial
region of the vocal cords (level of arytenoid projections). Histo-
pathological evaluation was performed by the histopathologist Dr.
A. Buettner at the Laboratory of Pharmacology and Toxicology
GmbH& Co. KG (Germany). Incidence of ﬁndings was recorded and
the severity of the lesions was evaluated using a scoring system of
0e5 in a blinded manner adapted from the published literature
(Coggins et al., 1980; Lewis, 1981; Young, 1981).
Bone marrow smears were prepared from sham, 3R4F_23, and
THS2.2_50 groups and recovery groups for sham, 3R4F_23, and
THS2.2_50. Bone marrow was collected from the left femur by
ﬂushing with HEPES-buffered saline solution (HBSS). Smears were
prepared by cytospin of bone marrow suspension onto glass slides.
Two bone marrow smears per animal were evaluated. Smears were
stained with Pappenheimer solution. The myeloid: erythroid ratio
was determined by evaluating cell differentiation of 200 nucleus-
containing cells.2.6.7. Statistical evaluation
Descriptive statistics (N, mean or median, standard deviation or
geometric standard deviation) of the main aerosol parameters
(TPM, CO, nicotine, formaldehyde, acetaldehyde, acrolein, and PSD)
were computed for each exposure chamber. For PSD, calculation
was performed using the SAR application. For the parameters of
aerosol biomonitoring (blood carboxyhemoglobin, selected nico-
tine and aerosol metabolites in urine, and respiratory physiology),
the number of valid measurements, mean, and standard deviation
or standard error of the mean were computed for each exposure
group and sex. For biological endpoints (body weight, food con-
sumption, lung inﬂammation, hematology, clinical chemistry, or-
gan weight, and pathology), descriptive statistics were computed
for each exposure group and sex. If the parameters were evaluated
on a continuous scale (e.g. body weights, organ weights, clinical
chemistry, and hematology parameters), basic statistics (number of
valid measurements, mean, standard deviation, standard error of
the mean) were computed. For ordinal parameters, such as histo-
pathology scorings, the number of valid measurements and fre-
quency table (absolute and relative to the number of valid
observations) were computed, as well as mean and standard de-
viation or standard error of themean. For incidence parameters, the
number of valid measurements and frequency table (absolute and
relative to the number of valid observations) were computed.
Additionally and separately for each sex, pairwise differences
between groups were estimated. Comparative statistics for respi-
ratory physiology, clotting potential, FACS cell counts, and relative
organ weights were computed using Student's two-sample t-test.
Comparative statistics for body weight, hematology, and clinical
chemistry were performed using the Provantis statistical reporting
template (Instem, UK); depending on the normality of data, either a
parametric test (ANOVA) or a non-parametric test was performed.
For incidences, comparative statistics were computed using Fisher's
exact test. For ordinal variables, the Cochran-Mantel-Haenszel test
was used with the row mean scores statistic (with the alternative
hypothesis that mean responses differ across compared groups, the
scores being deﬁned as integer scores). Finally, for data frommulti-
analyte proﬁles in BALF, as the number of values below the limit of
detection/quantiﬁcation was high for some analytes, a Mann-
Whitney- Wilcoxon rank sum test was performed.2.7. Transcriptomics endpoints
The transcriptomics analyses were performed on samples from
OECD Plus groups described in section 2.1.2.7.1. Tissue preparation
Prior to organ removal, the rats were whole-body perfused with
cold saline to remove blood cells through the heart ventricles. Sa-
line was introduced by insertion of a 20G needle into the left
ventricle of the heart at 30 ml/min using a peristaltic pump. An exit
cut was made at the right atrium of the heart to complete the ﬂow.
The perfusion was continued for approximately 8 min until the
lungs and liver lobes were blanched. The lung lobes were
embedded in optimal cutting temperature (OCT) compound and
cut along the coronal plane using a cryostat (Leica CM3050b). The
medial region of the left lung was cryosliced into serial sections of
40 mm each for total RNA including miRNA isolation. To isolate the
left respiratory nasal epithelium (RNE), the head was excised and
the lower jaw, fur, calvaria, and brain were removed from the skull.
An incision sagittal to the nose was made, and the nose was pried
into left and right halves before removing the RNE from the
exposed grooves. The RNE was removed using forceps and snap
frozen in liquid nitrogen for RNA/miRNA analysis.
Table 1
Characterization of test atmospheres e determinations performed in the exposure chambers.
Chamber TPM (mg/l) Particle size distribution Nicotine (mg/l) Carbon monoxide (ppm) Acetaldehyde (mg/l) Acrolein (mg/l) Formaldehyde (mg/l)
MMAD (mm) GSD
Sham 0.0 ± 0.0a (76) NM NM <LOQ <LOQ NM NM NM
3R4F_8 86.2 ± 9.9 (76) 0.56e0.86 (8) 1.11e1.44 7.20 ± 0.81 (32) 108.6 ± 10.5 5.68 ± 1.09 (15) 0.56 ± 0.11 (15) 0.19 ± 0.04 (15)
3R4F_15 168.6 ± 8.9 (76) 0.59e0.84 (11) 1.18e1.44 13.33 ± 1.22 (29) 196.0 ± 8.9 10.29 ± 1.28 (15) 1.00 ± 0.12 (15) 0.36 ± 0.05 (15)
3R4F_23 273.5 ± 17.1 (76) 0.59e0.76 (12) 1.19e1.42 21.68 ± 1.64 (28) 333.4 ± 15.2 16.77 ± 0.78 (14) 1.61 ± 0.11 (14) 0.53 ± 0.05 (14)
THS2.2_15 89.4 ± 10.2 (76) 0.45e0.87 (11) 1.01e1.64 13.66 ± 1.37 (76) 4.5 ± 0.5 2.20 ± 0.14 (14) 0.09 ± 0.01 (14) 0.07 ± 0.01 (14)
THS2.2_23 124.7 ± 27 (76) 0.40e0.98 (10) 1.24e1.63 21.72 ± 3.00 (76) 6.4 ± 0.6 3.37 ± 0.45 (15) 0.13 ± 0.02 (15) 0.10 ± 0.02 (15)
THS2.2_50 319.8 ± 33.8 (76) 0.44e0.83 (13) 1.20e1.58 47.25 ± 4.83 (76) 12.9 ± 0.8 6.81 ± 0.72 (15) 0.25 ± 0.03 (15) 0.19 ± 0.03 (15)
Results represent medians or mean ± standard deviation. Abbreviations: TPM, total particulate matter; MMAD, mass median aerodynamic diameter; GSD, geometric standard
deviation; NM, not measured. The sample size is in parentheses.
a TPM in Sham is deﬁned as zero where the difference in ﬁlter weight before and after collection is negative.
E.T. Wong et al. / Regulatory Toxicology and Pharmacology 81 (2016) S59eS81S642.7.2. Total RNA preparation and whole genome expression arrays
Lung sections were lysed in RLT buffer (Qiagen, Germany) and b-
mercaptoethanol using ceramic beads for homogenization. Total
RNA, including miRNA, was isolated using the miRNeasy Mini Kit
(Qiagen, Germany). RNA extraction from RNE was done using
QIAzol (Qiagen, Germany) lysis buffer and the miRNeasy Mini Kit.
The RNA quality of the RNE samples from the sham female group
was not sufﬁcient to reach a signiﬁcant sample size. Therefore, only
data from the male RNE and male lung are reported (section 3.7).
Transcriptomics data obtained from the female lung samples are
shown in Supplementary Fig. 3.2.7.3. Gene expression array data analysis
RNA was processed with the High Throughput 30 In Vitro Tran-
scription PLUS kit (Affymetrix, USA) for chip hybridization on
GeneChip® Rat Genome 230 2.0 arrays (Affymetrix, USA). Raw data
ﬁles were processed with the custom Chip Description File envi-
ronment Rat2302_Rn_ENTREZG v19.0.0 (rat2302rnentrezgcdf) (Dai
et al., 2005), and normalized using frozen-Robust Microarray
Analysis (fRMA) (McCall et al., 2010). The normalization vector
needed for fRMA was created using a set of 1023 microarray rat
samples from 11 tissues and the R package frmaTools version 1.18.0.
Quality controls, including log-intensities, normalized-unscaled
standard error, relative log expression, median absolute value RLE,
and pseudo-images, as well as raw image plots, were performed
with the affyPLM package (Bioconductor, USA) (Bolstad et al.,
2003). Following these quality control procedures, raw p-values
were generated for contrasts between sham and exposed groups
with the limma package (Smyth, 2004), and adjusted using the
BenjaminieHochberg false discovery rate (FDR) multiple test
correction (Gentleman et al., 2004). The gene expression data used
in this publication have been deposited in ArrayExpress (http://
www.ebi.ac.uk/arrayexpress/), and are accessible through acces-
sion number E-MTAB-4492.2.7.4. Systems biology network analysis
To quantitatively assess the perturbation of relevant biological
response systems, previously deﬁned causal network models were
used (Boue et al., 2015; Gebel et al., 2013; Schlage et al., 2011;
Westra et al., 2011, 2013) in conjunction with a network scoring
algorithm that predicts the perturbation of these networks based
on transcriptomics data (Martin et al., 2012, 2014). Brieﬂy, this
approach relies on two-layer causal network models, in which the
lower layer represents the transcriptional changes, and the upper
layer represents the actual causal network model. Both layers are
linked, and transcriptional changes in the lower layer are used to
deduce the activity of the components in the upper layer, which are
then aggregated into the ﬁnal network score. Themethod uses gene
expression data without a fold change or p-value cutoff. Thebiological mechanisms covered by the networks included in this
study are inﬂammation, cellular fate, tissue repair and angiogen-
esis, cellular stress, and cellular proliferation. Each biological pro-
cess can be decomposed into biological sub-processes to further
investigate the nature of the perturbation (Boue et al., 2015; Kogel
et al., 2014).3. Results
3.1. Test atmosphere composition
The concentrations of nicotine, TPM, CO, and aldehydes were
determined in the test atmospheres; Table 1 summarizes the re-
sults. Analysis of the test atmospheres throughout the inhalation
period indicated that the aerosol was reproducibly generated and
delivered to the exposure chambers. Nicotine concentrations ach-
ieved for 3R4F_23 and THS2.2_23 were very similar. At the same
nicotine concentration, the MA generated from THS2.2 contained
approximately 2-fold less TPM, 50-fold less CO, 5-fold less form-
aldehyde and acetaldehyde, and 12-fold less acrolein compared
withMS from 3R4F (Table 1). The PSDmeasurements indicated that
particle sizes and distributions were similar between the exposure
groups (Table 1), and were therefore similarly deposited in the
respiratory tract. Based on the PSD data, our results indicate that
particles were compatible with inhalation, and equally respirable
between all aerosol-exposed groups.3.2. In-life observations
After the exposure, the animals showed typical signs of stress
related to tube restraint and/or smoke exposure, regardless of the
type and concentration of test atmosphere they were exposed to
(Dalbey et al., 1980; Gaworski et al., 2009; Vanscheeuwijck et al.,
2002). This was manifested by post-exposure Harderian gland
secretion, wet fur, decreased reﬂexes, and increased irritability.
Observations made at the fundus of the eye during ophthalmos-
copy examinations were similar in both sham and aerosol exposed
groups, and no concentration- or test atmosphere-dependent ef-
fects were noted (data not shown). There were no numerical dif-
ferences in mortality between THS2.2 and 3R4F groups. Deaths
were considered either incidental or of technical origin
(Supplementary Table 10).
In contrast to the above signs and symptoms that were observed
across all exposure groups, higher incidences of wounds (on paws,
tail base), sneezing, and/or closed eyes were noted in the 3R4F_23
groups (25 incidences) and THS2.2_50 groups (18 incidences).
Wounds were probably due to animal movement in the exposure
tube and abrasion through contact with the restraint plunger;
closed eyelids were probably related to irritation from the aerosol
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The occurrence of tremors in rats was more frequent in the
THS2.2_50 group, mainly during the ﬁrst 15 days of exposure (7
incidences in female rats, 2 incidences in male rats), and after day
50 of the study (37 incidences in female rats, 14 incidences in male
rats). This may be attributed to the nicotine effect that was
observed in past study (Phillips et al., 2015a). The lower body
weights in female rats, in combination with high nicotine con-
centration exposure, may account for the higher incidence of
tremors. The animals with tremors recovered within 30 min upon
removal from the exposure. This is typical of nicotine toxicity, and
is related to the short half-life of nicotine in rats (Abobo et al.,
2012; Silvette et al., 1962).
3.3. Biomonitoring
3.3.1. Respiratory physiology
Determination of respiratory physiology parameters was per-
formed to assess the degree of irritation to the respiratory tract
(Alarie, 1981). Exposure to 3R4F caused a concentration-
dependent reduction in respiratory minute volume in both male
and female rats that was signiﬁcantly lower in the 3R4F_15 (male
only) and 3R4F_23 (bothmale and female) groups, compared with
the sham group (Tables 2 and 3). In contrast, the respiratory
minute volumes of rats exposed to MA generated from THS2.2
were largely unaffected compared with sham groups (both sexes),
and were signiﬁcantly higher in comparison with 3R4F groups at
the same nicotine concentrations of 15 mg/l (male only) and 23 mg/l
(both sexes). The reduction in respiratory minute volume in 3R4F
groups was mainly attributed to a reduction in respiratory fre-
quency (both sexes) and tidal volume in male rats (Supplementary
Tables 11,12). Respiratory frequency and tidal volume remained
largely unaffected in THS2.2-exposed rats, and were higher than
those in the 3R4F_15 (female) and 3R4F_23 (male and female rats)
groups at the same nicotine concentrations. There was no signif-
icant change in peak inspiratory ﬂow in male groups except in the
3R4F_8 group, where it was considered an incidental ﬁnding. The
peak inspiratory ﬂow in the female THS2.2_15 and THS2.2_23
groups was higher compared with the sham group.
3.3.2. Biomarkers of exposure
Measurement of COHb in blood was performed to assess the
exposure and uptake of aerosols by the rats (Table 4). The pro-
portions of COHb were up to 26.5% in male rats exposed to 3R4F,
and only 4.5% in rats exposed to THS2.2. Similar results were ob-
tained from the exposed female rats (Supplementary Table 13).
There was also a good linear correlation between the proportions
of COHb in the exposed animals and the CO concentrations in the
test atmospheres, indicating efﬁcient uptake of the aerosols by the
animals (Supplementary Fig. 1). Measurements were repeated at
the end of the recovery period, and showed that all COHb values
were at baseline level (data not shown).
The second approach to assess aerosol exposure and uptake
was the quantiﬁcation of total nicotine metabolites in 24-h urine
(during and after exposure) collected from rats at deﬁned intervals
during the study. As controls, nicotine metabolites quantiﬁed
before the 90-day exposure phase and during the 42-day recovery
phase were determined; the results obtained were all below the
limit of quantiﬁcation. The lower limits of quantiﬁcation (LOQ)
were 1.73 mmol/l for 30HOCOT, 0.91 mmol/l for NCOT,1.31 mmol/l for
COT, 5.23 mmol/l for NNO, and 1.75 mmol/l for NNIC. In exposed
animals, the total quantity of nicotine metabolites excreted was
proportional to the nicotine test atmosphere concentrations
(Table 1, Supplementary Table 13). Similar results were obtained
for both sexes. At equal nicotine concentrations in the test
Table 3
Statistically signiﬁcant differences in body weight, food consumption, and respi-
ratory minute volume between animals exposed to aerosol from THS2.2 and
cigarette smoke from 3R4F.
Parameter Sex THS2.2_15
vs. 3R4F_15
THS2.2_23
vs. 3R4F_23
THS2.2_50
vs. 3R4F_23
Body weight on day 88 M ¼ [* ¼
F ¼ [** [**
Food consumption M ¼ ¼ [**
F ¼ [*** [***
Respiratory minute volume M [** [** [***
F ¼ [* [**
Difference between groups: Signiﬁcance: *, p < 0.05; **p < 0.01; ***, p < 0.001.
Symbols, [ indicates response higher in THS2.2 relative to 3R4F;¼indicates no
difference. Abbreviations: M, male; F, female.
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E.T. Wong et al. / Regulatory Toxicology and Pharmacology 81 (2016) S59eS81S66atmosphere, the total quantity of nicotine metabolites excreted
was higher in the THS2.2-exposed rats than in the 3R4F-exposed
rats. This is suggestive of an overall higher uptake of aerosol
constituents in the THS2.2-exposed rats. In the exposed animals,
the total quantity of nicotine metabolites excreted was similar
across the 3 time points (week 2, week 4, and week 12), indicating
a stable exposure and uptake of aerosol by the rats throughout the
study (Supplementary Fig. 1). The relative distribution of the 5
nicotine metabolites measured was in line with observations in
past studies, where NNO and COT were the major metabolites
excreted (Supplementary Fig. 1)(Kogel et al., 2014;
Vanscheeuwijck et al., 2002).
The third approach to assess aerosol exposure and uptake was
the quantiﬁcation of CEMA (metabolite of acrylonitrile), HPMA
(metabolite of acrolein), total NNAL (metabolite of NNK), and
SPMA (metabolite of benzene) in 24-h urine of exposed rats
(Table 4). In males, the levels of CEMA, HPMA, NNAL, and SPMA
were approximately 48-fold, 2-fold, 5-fold, and 38-fold, respec-
tively, lower in the THS2.2-exposed groups than in the 3R4F
groups at equal nicotine exposure concentrations. Among these 4
biomarkers of exposure, the concentration of HPMA was notably
higher compared with NNAL, CEMA, and SPMA in the sham and
pre-exposed animals. This may be related to endogenous pro-
duction of acrolein that contributes to the baseline levels of HPMA
in urine (Stevens, 2008). The baseline levels of the 4 biomarkers
were reﬂected in the urine samples collected before the 90-day
exposure phase and during the 42-day recovery phase
(Supplementary Fig. 1). As observed with nicotine metabolites,
the excretion of CEMA, HPMA, NNAL, and SPMA was also fairly
stable across the 13-week exposure period (measured in week 2,
week 4, and week 12), indicating a reproducible aerosol genera-
tion and uniform uptake of aerosol constituents by the rats
throughout the study (Supplementary Fig.1). The concentration of
HPMA excreted in the urine was proportional to the acrolein
levels in the test atmosphere supplied (Supplementary Fig. 1).
3.4. General and systemic effects
3.4.1. Body weight and food consumption. The animals gained
weight over time throughout the exposure period, and more
rapidly during the recovery period (Fig. 1). Body weight deter-
mination was made one day after the weekend exposure break,
during which animals had a short recovery, but also at the end of a
week of exposure. This explains the zig-zag pattern of the body
weights. In male rats, all aerosol-exposed animals showed lower
body weight when compared with sham. After the 90-day expo-
sure period to the test atmospheres, body weight was 10e18%
lower in the 3R4F groups, and 8e14% lower in THS2.2 groups,
compared with sham (Table 2). At equivalent nicotine concen-
trations (23 mg/l nicotine), the mean body weight in the male
Fig. 1. Mean body weights of (A) male and (B) female rats exposed to fresh air
(sham) and aerosols from THS2.2 and 3R4F. Animals were weighed twice per week.
Day 1 represents the exposure start date. N ¼ 6e20.
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no difference was found between the 3R4F_15 group and the
THS2.2_15 group (Table 3). In female rats, the body weight loss in
the sham group during the ﬁrst week of dose adaptation and slow
weight gain in subsequent exposure weeks resulted in lower
mean body weight in the sham group compared with the test and
reference groups throughout the study (Fig. 1). As a result, body
weight after the 90-day exposure period was 5e11% higher in the
3R4F groups and 7e17% higher in the THS2.2 groups, compared
with the sham group (Table 2). The mean body weight in the
3R4F_23 female group was lower than that in both the THS2.2_23
and THS2.2_50 groups (Table 3). Similar ﬁndings have been re-
ported for MS inhalation studies (Terpstra et al., 2003;
Vanscheeuwijck et al., 2002). The reduction in body weight is
likely due to the aerosol toxicity and irritation-dependent stress;
both nicotine (Chowdhury, 1990; Chowdhury et al., 1989) and
acrolein (Bouley et al., 1975; Feron et al., 1978) have been shown to
cause this effect.
Food consumption did not differ between the 3R4F and sham
groups. However, food consumption was higher in the male
THS2.2_50 group compared with the sham and 3R4F_23 groups.
In female rats, food consumption in the THS2.2_23 and THS2.2_50
groups was statistically higher than in the sham and 3R4F_23
groups (Tables 2 and 3).
3.4.2. Hematology. Blood neutrophil counts were signiﬁcantly
higher in the 3R4F_15 and 3R4F_23 male groups, as well as in the
THS2.2_50male 90-day exposed groups, compared with the sham
group (Table 5). An aerosol concentration-dependent increase in
neutrophil counts was observed for all 3R4F and THS2.2 90-day
exposed female rats. No signiﬁcant difference in neutrophil
counts was observed between the 3R4F and THS2.2 exposed
groups. After the 42-day recovery period, the neutrophil counts in
Table 6
Clinical chemistry parameters from male and female rats after 90-day inhalation period or 42-day recovery period following 90-day exposure to test atmosphere of the reference cigarette 3R4F, THS2.2, or air (sham).
Parameter Sex 90d 90 þ 42d
Sham 3R4F_8 3R4F_15 3R4F_23 THS2.2_15 THS2.2_23 THS2.2_50 Sham 3R4F_23 THS2.2_50
Alkaline
phosphatase
(IU/l)
M 162.0 ± 16.00 (10) 191.5 ± 16.00 (10) 193.9 ± 17.60 (10) 255.0 ± 20.70 (10)** 186.4 ± 15.90 (10) 235.0 ± 19.00 (9)** 254.0 ± 24.70 (10)** 149.6 ± 14.70 (6) 133.2 ± 15.60 (5) 169.8 ± 13.60 (10)
F 111.0 ± 9.60 (10) 158.2 ± 19.40 (10)* 149.1 ± 11.50 (9)* 182.0 ± 19.20 (9)** 146.7 ± 15.50 (10) 179.3 ± 22.80 (10)** 265.0 ± 32.70 (10)** 128.0 ± 15.00 (6) 129.0 ± 15.00 (5) 83.9 ± 7.40 (10)#
Alanine
aminotransferase
(IU/l)
M 57.0 ± 6.50 (10) 52.3 ± 5.00 (10) 63.7 ± 4.00 (10) 68.0 ± 5.80 (10) 64.2 ± 4.60 (10) 98.0 ± 18.00 (8)** 75.0 ± 6.70 (10)* 61.3 ± 11.50 (6) 47.9 ± 5.00 (5) 57.3 ± 7.50 (10)
F 51.0 ± 4.40 (10) 54.9 ± 6.90 (10) 55.9 ± 4.30 (9) 54.0 ± 2.60 (9) 67.6 ± 6.10 (10)* 74.6 ± 7.20 (10)** 73.0 ± 3.20 (10)** 68.5 ± 14.30 (6) 47.0 ± 2.00 (5) 52.4 ± 8.90 (9)
Aspartate
aminotransferase
(IU/l)
M 121.0 ± 8.90 (10) 134.2 ± 7.70 (10) 164.6 ± 10.70 (10)* 152.0 ± 16.80 (10) 160.5 ± 13.60 (10)* 209.0 ± 30.00 (8)** 158.0 ± 16.00 (10)* 108.4 ± 17.30 (6) 89.5 ± 2.80 (5) 108.5 ± 8.80 (10)
F 146.6 ± 13.40 (10) 165.5 ± 36.70 (10) 130.2 ± 12.50 (9) 122.8 ± 11.10 (9) 147.7 ± 13.70 (10) 124.0 ± 7.80 (10) 146.0 ± 7.50 (10) 166.0 ± 24.50 (6) 91.0 ± 8.00 (5)## 114.6 ± 17.50 (9)#
Total protein (g/l) M 58.8 ± 0.80 (10) 57.4 ± 1.00 (10) 58.2 ± 1.00 (10) 58.4 ± 0.40 (10) 56.2 ± 0.80 (10) 61.0 ± 3.00 (9) 58.3 ± 1.40 (10) 59.7 ± 1.30 (6) 62.9 ± 1.80 (5) 59.4 ± 0.90 (10)
F 64.0 ± 1.30 (10) 56.0 ± 1.60 (10)** 57.4 ± 0.90 (9)** 57.0 ± 0.90 (9)** 56.8 ± 0.90 (10)** 54.7 ± 0.80 (10)** 58.0 ± 0.60 (10)** 71.0 ± 1.20 (6) 66.0 ± 3.50 (5)# 62.8 ± 1.10 (10)##
Albumin (g/l) M 34.8 ± 0.40 (10) 33.7 ± 0.70 (10) 34.1 ± 0.70 (10) 34.7 ± 0.20 (10) 32.6 ± 0.40 (10)** 35.7 ± 1.30 (9) 34.4 ± 0.80 (10) 34.9 ± 0.60 (6) 35.0 ± 0.90 (5) 33.6 ± 0.60 (10)
F 38.9 ± 0.80 (10) 34.2 ± 0.90 (10)** 34.0 ± 0.70 (9)** 33.6 ± 0.40 (9)** 33.6 ± 1.00 (10)** 33.1 ± 0.60 (10)** 34.3 ± 0.50 (10)** 42.7 ± 0.80 (6) 38.1 ± 2.30 (5)## 36.6 ± 0.90 (10)##
Globulin (g/l) M 23.9 ± 0.50 (10) 23.7 ± 0.60 (10) 24.2 ± 0.50 (10) 24.0 ± 0.40 (10) 23.5 ± 0.60 (10) 24.2 ± 1.60 (10) 23.8 ± 0.90 (10) 25.0 ± 0.70 (6) 27.9 ± 1.20 (5)# 25.7 ± 0.50 (10)
F 25.0 ± 0.60 (10) 21.8 ± 0.90 (10)* 23.5 ± 0.40 (9) 23.8 ± 1.10 (9) 23.2 ± 0.70 (10) 21.6 ± 0.70 (10)** 24.1 ± 0.80 (10) 28.7 ± 0.50 (6) 28.0 ± 1.80 (5) 26.1 ± 1.20 (10)
Cholesterol
(mmol/l)
M 1.3 ± 0.08 (10) 1.1 ± 0.08 (10) 1.0 ± 0.05 (10)** 0.9 ± 0.04 (10)** 1.1 ± 0.05 (10)** 1.0 ± 0.07 (9)** 1.0 ± 0.08 (10)** 1.2 ± 0.07 (6) 1.3 ± 0.10 (5) 1.3 ± 0.11 (10)
F 1.4 ± 0.09 (10) 0.9 ± 0.06 (10)** 0.8 ± 0.07 (9)** 0.8 ± 0.08 (9)** 1.0 ± 0.08 (10)** 0.9 ± 0.07 (10)** 1.0 ± 0.06 (10)** 1.7 ± 0.09 (6) 1.6 ± 0.26 (5) 1.4 ± 0.07 (10)#
Triglyceride
(mmol/l)
M 1.2 ± 0.16 (10) 1.0 ± 0.09 (10) 0.7 ± 0.11 (10)** 0.8 ± 0.09 (10) 0.7 ± 0.08 (10)** 1.2 ± 0.12 (8) 0.8 ± 0.15 (10)* 1.3 ± 0.24 (6) 1.4 ± 0.33 (5) 1.5 ± 0.24 (10)
F 0.9 ± 0.11 (10) 0.8 ± 0.10 (10) 0.4 ± 0.08 (9)** 0.3 ± 0.05 (9)** 0.9 ± 0.15 (10) 0.7 ± 0.14 (10) 0.4 ± 0.06 (10)** 1.8 ± 0.32 (6) 1.2 ± 0.27 (5) 1.5 ± 0.17 (10)
Glucose (mmol/l) M 12.5 ± 0.70 (10) 10.9 ± 0.50 (10)* 11.5 ± 1.40 (10) 10.0 ± 0.60 (10)** 11.4 ± 0.50 (10) 16.6 ± 4.10 (8) 9.6 ± 0.60 (10)** 13.4 ± 0.70 (6) 14.5 ± 2.70 (5) 14.5 ± 3.00 (10)
F 10.5 ± 0.40 (10) 11.6 ± 1.10 (10) 10.9 ± 1.30 (9) 8.6 ± 0.30 (9)** 11.5 ± 1.50 (10) 9.4 ± 0.40 (10) 8.4 ± 0.40 (10)** 10.2 ± 0.40 (6) 11.6 ± 1.80 (5) 11.0 ± 0.30 (10)
Clinical chemistry parameters measured after 90-day exposure (90d) and 42-day recovery period following a 90-day exposure (90 þ 42d). Results represent mean ± standard error. The sample size is in parentheses. Difference
from sham group at 90d: Signiﬁcance: *, p < 0.05; **p < 0.01. Difference from sham group at 90 þ 42d: Signiﬁcance: #, p < 0.05; ##p < 0.01. Abbreviations: M, male; F, female.
Table 7
Statistical signiﬁcance difference in activities of liver enzymes and triglycerides present in serum.
Parameter Sex 90d 90 þ 42d
THS2.2_15 vs. 3R4F_15 THS2.2_23 vs. 3R4F_23 THS2.2_50 vs. 3R4F_23 THS2.2_50 vs. 3R4F_23
Alkaline phosphatase (IU/L) M ¼ ¼ ¼ ¼
F ¼ ¼ [* Y*
Alanine aminotransferase (IU/L) M ¼ ¼ ¼ ¼
F ¼ [* [** ¼
Aspartate aminotransferase (IU/L) M ¼ [* ¼ ¼
F ¼ ¼ ¼ ¼
Triglyceride (mmol/L) M ¼ [* ¼ ¼
F [** [** ¼ ¼
Difference between groups: Signiﬁcance: *, p < 0.05; **p < 0.01. Symbols, Y indicates response lower in THS2.2 relative to 3R4F; [ indicates response higher in THS2.2 relative to 3R4F;¼indicates no difference. Abbreviations: M,
male; F, female.
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E.T. Wong et al. / Regulatory Toxicology and Pharmacology 81 (2016) S59eS81 S69male rats declined to levels similar to those in the sham group. In
female rats, the neutrophil counts were signiﬁcantly lower after
the 42-day recovery period, compared with the 90-day exposure
groups, even though the level in the THS2.2_50 group was still
slightly higher than in the sham recovery group.
Lymphocyte counts were statistically signiﬁcantly lower in the
3R4F_23 male group when compared with the sham group on day
90 (Table 5). No change in lymphocyte counts was observed for the
female animals. Lymphocyte counts were slightly lower in the
male THS2.2 groups, compared with the sham group. A statisti-
cally signiﬁcant difference was observed for the THS2.2_15 group,
even though no concentration-dependent effect was observed. No
signiﬁcant difference in lymphocyte counts was observed be-
tween the 3R4F and THS2.2 exposed groups. After the 42-day re-
covery period, the lymphocyte counts in the sham, 3R4F_23, and
THS2.2_50 male groups were increased, compared with the same
groups at 90-day. A statistically signiﬁcant difference was
observed for the THS2.2_50 group compared with the sham group
after the 42-day recovery period.
A small but signiﬁcantly higher monocyte count in the
THS2.2_23 and THS2.2_50 groups was observed relative to the
sham group in female rats (Supplementary Table 14). The mono-
cyte count, however, was not different between the 3R4F- and
THS2.2-exposed groups.
The red blood cell (RBC) parameters (erythrocyte count, retic-
ulocyte count, blood hemoglobin (Hb) concentration, mean
corpuscular volume (MCV), mean cell hemoglobin content
(MCHC), mean corpuscular hemoglobin (MCH), and hematocrit
(HCT)) did not show any consistent exposure-related effects
(Supplementary Table 14), and results for all groups were within
the range of normal values provided by the breeders (Thrall, 2012).
3.4.3. Clinical chemistry. Serum was collected during necropsy
after 90 days of exposure and after 42 days post-exposure from the
abdominal aorta of rats for the analysis of various clinical chem-
istry parameters. The most obvious aerosol effects were observed
in the activities of liver-derived enzymes. The activity of alkaline
phosphatase (ALP) was increased and statistically signiﬁcant
compared with the sham after 90 days of exposure in the male
3R4F_23 group and in all female 3R4F groups, while aspartate
aminotransferase (AST) activity was higher in the male 3R4F_15
group (Table 6). Compared with sham, the ALP and alanine
aminotransferase (ALT) activities were higher in the male and
female THS2.2 groups, while AST activity was higher in the male
THS2.2-exposed groups. The liver-derived enzyme activities were
in general similar between the THS2.2 and 3R4F groups at the
same nicotine concentrations (Table 7). The enzyme activities in
the 3R4F and THS2.2_50 groups reverted back to levels similar to
those in the sham group after the 42-day recovery period.
Some aerosol-dependent effects were also observed in the
markers of nutritional/metabolic status, including proteins, lipids,
and glucose (Table 6). The concentrations of albumin and total
protein were unchanged in the male 3R4F groups. Albumin was
reduced relative to the sham group in the male THS2.2_15 group,
but not in the other concentration groups, and hence is considered
an incidental observation. The 3R4F- and THS2.2-exposed female
groups had lower albumin and total serum protein concentrations
compared with the sham group after a 90-day exposure. The
concentrations of albumin and total protein in the female sham
group were also lower compared with the same group after the
42-day recovery period. The levels of both analytes in exposed
groups were partially reversed toward sham group levels in the
post-exposure recovery animals.
Serum cholesterol concentration was lowered in a
concentration-dependent manner in all the 3R4F- and THS2.2-
Table 9
Statistical signiﬁcance difference in BALF cell counts between animals exposed to aerosol from THS2.2 and cigarette smoke from 3R4F.
Parameter Sex 90d 90 þ 42d
THS2.2_15 vs. 3R4F_15 THS2.2_23 vs. 3R4F_23 THS2.2_50 vs. 3R4F_23 THS2.2_50 vs. 3R4F_23
Total cell count M Y* Y** Y** ¼
F Y** Y*** Y*** ¼
Macrophage count M ¼ Y* ¼ ¼
F ¼ Y* Y** ¼
Lymphocyte count M Y** Y*** ¼ Y*
F ¼ ¼ Y** Y*
Neutrophil count M Y*** Y*** Y*** Y***
F Y*** Y*** Y*** Y**
Eosinophil count M ¼ Y*** Y*** Y***
F Y*** Y** Y*** Y**
Difference between groups: Signiﬁcance: *, p < 0.05; **p < 0.01; ***p < 0.001. Symbols, Y indicates response lower in THS2.2 relative to 3R4F; ¼indicates no difference.
Abbreviations: M, male; F, female.
Fig. 2. Analytes present in bronchoalveolar lavage ﬂuid after 90 days of exposure and 42 days of recovery (R). Data shown are row z-scores for each analyte (y-axis) and for each
exposure group (x-axis) in (A) male and (B) female rats. Note: Analytes with 50% or more values below limit of quantiﬁcation (LOQ) were excluded from the heatmaps. N ¼ 5e10.
E.T. Wong et al. / Regulatory Toxicology and Pharmacology 81 (2016) S59eS81S70
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E.T. Wong et al. / Regulatory Toxicology and Pharmacology 81 (2016) S59eS81 S71exposed male and female groups. Triglyceride levels showed the
same general trend in the 3R4F- and THS2.2-exposed male and
female groups compared with the sham groups (Table 6). There
was no difference in cholesterol (both sexes) and triglycerides
(male only) concentration between the 3R4F and THS2.2 groups;
in female rats, the concentrations of triglycerides in the 3R4F
groups were lower than those in the THS2.2 groups at the same
nicotine exposure concentrations. The concentrations returned to
basal levels similar to those in the sham group in the post-
exposure recovery animals (Table 6).
Serum glucose concentrations were slightly lower in the male
3R4F_8 and 3R4F_23 groups relative to the sham group on day 90
(Table 6). No difference was observed compared with the male
recovery groups. In female rats, blood glucose was lower in the
3R4F_23 group, and the levels returned to baseline in the recovery
groups. Blood glucose was lower in both the male and female
THS2.2_50 groups, compared with the sham group. The glucose
concentrations returned to sham levels (female only) after the
post-exposure recovery period. The remaining serum analytes
showed either minor changes or no exposure effects (data not
shown).
3.4.4. Clotting potential. The results from PT and APTT were used
to determine the efﬁciency of extrinsic and intrinsic pathways of
coagulation, respectively. In male rats, the measured PTs were
either within or marginally above the reference range for this
strain of rat (Lee et al., 2012). The PT data from female rats and
APTT from both sexes were within the reference range for this
strain (Lee et al., 2012). No signiﬁcant difference was detected
between the 3R4F and THS2.2 groups for both PT and APTT (data
not shown).
3.4.5. Lung lavage and analysis. The degree of inﬂammation in the
lungs caused by test atmosphere from 3R4F and THS2.2 was
evaluated by the quantiﬁcation of free lung cells and the proﬁling
of cytokines present in BALF. Exposure to 3R4F in both male and
female groups caused a concentration-dependent increase in total
free lung cell count compared with sham, whereas only the female
THS2.2_23 group showed statistically signiﬁcant higher count
(Tables 8 and 9). Among the free lung cells, the neutrophil and
eosinophil cell counts were increased in a concentration-
dependent manner in all 3R4F groups for both male and female
rats compared with the sham groups, while no signiﬁcant increase
was noted in the THS2.2-exposed groups. The macrophage and
lymphocyte counts showed a trend of increase in the male 3R4F-
exposed groups, while no increase was noted in the THS2.2 groups
(Tables 8 and 9). In females, macrophage and lymphocyte counts
were increased in the 3R4F groups comparedwith the sham group,
while no increase was noted in the THS2.2 groups, with the
exception of a marginal increase in macrophage counts in the
THS2.2_23 female group. In summary, the accumulation of in-
ﬂammatory cells in the BALF of 3R4F-exposed rats was consistent
with ﬁndings from previous studies (Fujimoto et al., 2015; Kogel
et al., 2014; Piade et al., 2014). Low numbers of immune cells in
rats exposed to THS2.2 aerosol are reﬂective of a low degree of
pulmonary inﬂammation in the lung, and are consistent with
lower concentrations of irritants in the aerosol of the THS2.2 test
atmosphere, compared with 3R4F (Schaller et al., submitted (this
issue)-a).
Multiple analyte proﬁling (RodentMAP™) was performed on
BALF to quantify 60 analytes; 30 out of 60 analytes had at least 50%
of values below the lower limit of quantiﬁcation for all the OECD
groups. Data from the quantiﬁable analytes are summarized in
Fig. 2. Analytes with signiﬁcant exposure effects can be summa-
rized as follows: Exposure to 3R4F caused a concentration-
Table 11
Statistical signiﬁcance difference in relative organ weights between animals exposed to aerosol from THS2.2 and cigarette smoke from 3R4F.
Parameter Sex 90d 90 þ 42d
THS2.2_15 vs. 3R4F_15 THS2.2_23 vs. 3R4F_23 THS2.2_50 vs. 3R4F_23 THS2.2_50 vs. 3R4F_23
Lung, larynx, trachea M ¼ Y*** Y*** ¼
F ¼ Y*** Y*** Y*
Left adrenal M ¼ ¼ ¼ ¼
F ¼ ¼ ¼ ¼
Right adrenal M ¼ Y* ¼ ¼
F ¼ ¼ ¼ ¼
Thymus M ¼ ¼ ¼ ¼
F ¼ ¼ ¼ Y*
Spleen M ¼ [*** ¼ ¼
F ¼ ¼ ¼ ¼
Liver M ¼ ¼ ¼ ¼
F ¼ ¼ [** ¼
Uterus F ¼ ¼ Y* ¼
Difference between groups: Signiﬁcance: *p < 0.05; **p < 0.01; ***p < 0.001. Symbols, Y indicates response lower in THS2.2 relative to 3R4F; [ indicates response higher in
THS2.2 relative to 3R4F; ¼indicates no difference. Abbreviations: M, male; F, female.
E.T. Wong et al. / Regulatory Toxicology and Pharmacology 81 (2016) S59eS81S72dependent increase in some inﬂammatory cytokines and factors
associated with inﬂammation (e.g. M-CSF, MCP1, MDC, FGF9, and
VEGFA) relative to sham, but the levels were not signiﬁcantly
higher in any of the THS2.2-exposed groups. The concentrations of
other analytes (e.g. MIP-1b, MCP3, MPO and PAI-1), although
increased in the THS2.2-exposed groups, were signiﬁcantly lower
when compared with the 3R4F_15 and 3R4F_23 groups of both
sexes. At the end of the 42-day recovery period, the effects of 3R4F
exposure on most of the previously upregulated analytes were
reduced but still higher than those in the sham group (Fig. 2). The
RodentMAP™ results are consistent with lowered numbers of in-
ﬂammatory cells in the BALF collected from THS2.2-exposed rats.3.5. Respiratory tract organs
Higher weights of lungs relative to body weight compared with
sham were observed in the 3R4F-exposed animals, and to a lesser
extent in THS2.2 and post-exposure groups (Tables 10 and 11).
Higher relative weights of lungs (with trachea and larynx) are
typical of smoke-exposed lungs (Gaworski et al., 1997, 1999;
Vanscheeuwijck et al., 2002). Lower organ weights in the THS2.2
groups compared with 3R4F were consistent with reduced inﬁl-
tration of inﬂammatory cells in the lung, and corroborated with the
histopathological ﬁndings. Histopathological ﬁndings in 3R4F-
exposed groups were consistent with published data (Coggins et al.,
1980, 1989; Gaworski et al., 1997; Piade et al., 2014;
Vanscheeuwijck et al., 2002). Histopathological evaluation of the
lungs and other respiratory tract organs showed signiﬁcantly lower
severity scores in the THS2.2-exposed animals compared with
3R4F-exposed animals. The parameters listed in Table 12 are
summarized here.
The nasal lesions observed predominantly in 3R4F-exposed rats
included reserve cell hyperplasia of the respiratory epithelium,
squamous epithelial metaplasia of the respiratory epithelium and
olfactory epithelium, corniﬁcation of the metaplastic respiratory
epithelium, presence of neutrophilic granulocytes, loss of goblet
cells at the septum, atrophy of olfactory epithelium, loss of nerve
bundles at the lamina propria of olfactory epithelium, and mixed
inﬂammatory cells at the lamina propria of the olfactory epithe-
lium. Severity scores observed in THS2.2-exposed animals were
signiﬁcantly lower than those in 3R4F-exposed groups (Table 12,
Table 13). The incidences of the changes described above at nose
level 2 to 4 were signiﬁcantly lower in the THS2.2 groups,
compared with the 3R4F groups. Being obligatory nose breathers,
an exception was at the more sensitive nose level 1 of the rats
(Renne et al., 2009), where the incidences of reserve cellhyperplasia, squamous cell metaplasia, and the loss of goblet cells
do not differ between the 3R4F- and THS2.2-exposed groups. After
the 42-day recovery period, the severity scores of many of the
ﬁndings in the 3R4F-exposed groups were reduced. For the ﬁndings
at nose level 1, the mean severity scores were still lower for the
THS2.2_50 group, compared with the 3R4F_23 group after the 42-
day recovery period.
Changes observed in the larynx in response to 3R4F exposure
(moderate to high severity score) were signiﬁcantly lower in
THS2.2-exposed animals (low severity score); these changes
included squamous epithelial metaplasia, corniﬁcation, and hy-
perplasia of the epithelium (Tables 12,13). While the incidences of
the observed laryngeal changes were signiﬁcantly lower in the
THS2.2 groups compared with the 3R4F groups, only the incidence
of hyperplasia at the lower medial region of the larynx was the
same in the test and reference item groups. At 42 days post expo-
sure, the severity and incidences of squamous epithelial metaplasia
and the amount of corniﬁcation were reduced in all locations,
exposure groups and sexes. Epithelial hyperplasia and squamous
epithelial metaplasia at the laryngeal epithelia, the epithelial
thickness measured at the ﬂoor of the larynx and at the lower
medial region of the vocal cords, were larger in the 3R4F groups
compared with the THS2.2 groups (Supplementary Tables 15,16). At
42 days post exposure, a reduction was observed in the epithelial
thickness in the 3R4F- and THS2.2-exposed groups, but the
epithelial thickness measured in the 3R4F_23 group was still
greater than that in the THS2.2_50 group.
Histopathological ﬁndings, including reserve cell hyperplasia
and goblet cell hyperplasia at the tracheal epithelium, were
observed at the tracheal ring and bifurcation in response to 3R4F
exposure (low severity score) but absent from THS2.2-exposed
animals (Table 13). Both ﬁndings were reversed in the 3R4F 42-
day post-exposure groups.
The severity scores for changes observed in the left lung in
response to 3R4F exposure were moderate to high. The severity
scores were signiﬁcantly lower in THS2.2-exposed animals, where
the changes were either of low severity score or absent (Table 13).
The changes included the presence of macrophages with and
without yellow pigmentation in the alveolar lumen, the presence of
neutrophilic granulocytes in the alveolar lumen, and goblet cell
hyperplasia at the main bronchus. Incidences of these ﬁndings
were also signiﬁcantly lower in the THS2.2-exposed animals. The
severity scores of the ﬁndings were reduced in the post-exposure
groups.
Table 12
Histopathological ﬁndings in the respiratory tract of male and female rats after 90-day inhalation period or 42-day recovery period following 90-day exposure to test atmosphere of the reference cigarette 3R4F, THS2.2, or air
(sham).
Localization Tissue type Observation Sex 90d 90 þ 42d
Sham 3R4F_8 3R4F_15 3R4F_23 THS2.2_15 THS2.2_23 THS2.2_50 Sham 3R4F_23 THS2.2_50
Nose level 1 Respiratory epithelium Reserve cell
hyperplasia
M 0.5 ± 0.17 (5/10) 3.6 ± 0.16 (10/10)*** 4.1 ± 0.10 (10/10)*** 4.6 ± 0.16 (10/10)*** 2.2 ± 0.36 (10/10)*** 2.9 ± 0.10 (10/10)*** 3.7 ± 0.15 (10/10)*** 0.5 ± 0.22 (3/6) 2.6 ± 0.40 (5/5)## 1.3 ± 0.26 (8/10)
F 0.1 ± 0.10 (1/10) 3.9 ± 0.18 (10/10)*** 4.1 ± 0.10 (10/10)*** 4.8 ± 0.15 (9/9)*** 2.0 ± 0.21 (10/10)*** 2.6 ± 0.16 (10/10)*** 3.6 ± 0.16 (10/10)*** 0.0 ± 0.00 (0/6) 2.5 ± 0.22 (6/6)## 1.2 ± 0.28 (7/9)##
Squamous epithelial
metaplasia
M 0.0 ± 0.00 (0/10) 2.5 ± 0.17 (10/10)*** 3.4 ± 0.16 (10/10)*** 4.0 ± 0.00 (10/10)*** 0.7 ± 0.40 (4/10)* 1.5 ± 0.17 (10/10)*** 2.9 ± 0.23 (10/10)*** 0.2 ± 0.17 (1/6) 4.0 ± 0.00 (5/5)## 0.8 ± 0.36 (4/10)
F 0.0 ± 0.00 (0/10) 3.0 ± 0.00 (10/10)*** 3.9 ± 0.10 (10/10)*** 4.0 ± 0.00 (9/9)*** 1.0 ± 0.21 (8/10)*** 1.5 ± 0.17 (10/10)*** 3.2 ± 0.25 (10/10)*** 0.0 ± 0.00 (0/6) 4.0 ± 0.00 (6/6)### 1.3 ± 0.41 (6/9)#
Amount of
corniﬁcation
M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 1.0 ± 0.39 (5/10)* 2.8 ± 0.29 (10/10)*** 0.4 ± 0.40 (1/10) 0.0 ± 0.00 (0/10) 0.4 ± 0.31 (2/10) 0.0 ± 0.00 (0/6) 2.2 ± 0.37 (5/5)## 0.0 ± 0.00 (0/10)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 1.2 ± 0.44 (6/10)** 3.9 ± 0.11 (9/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 1.0 ± 0.42 (4/10)* 0.0 ± 0.00 (0/6) 2.5 ± 0.22 (6/6)## 0.0 ± 0.00 (0/9)
Loss of goblet cells
(septum)
M 0.4 ± 0.22 (3/10) 3.1 ± 0.18 (10/10)*** 4.5 ± 0.17 (10/10)*** 4.6 ± 0.16 (10/10)*** 1.9 ± 0.46 (9/10)** 2.0 ± 0.26 (10/10)*** 3.4 ± 0.16 (10/10)*** 0.8 ± 0.31 (4/6) 2.2 ± 0.66 (4/5) 1.4 ± 0.31 (8/10)
F 0.3 ± 0.17 (3/9) 3.8 ± 0.20 (10/10)*** 4.6 ± 0.16 (10/10)*** 4.7 ± 0.17 (9/9)*** 1.3 ± 0.26 (9/10)** 2.1 ± 0.23 (10/10)*** 3.9 ± 0.10 (10/10)*** 0.2 ± 0.17 (1/6) 3.7 ± 0.21 (6/6)## 1.4 ± 0.44 (7/9)#
Neutrophilic
granulocytes
M 0.1 ± 0.10 (1/10) 0.3 ± 0.15 (3/10) 0.5 ± 0.22 (4/10) 0.8 ± 0.29 (5/10)* 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.1 ± 0.10 (1/10) 0.0 ± 0.00 (0/6) 0.2 ± 0.22 (1/5) 0.1 ± 0.1 (1/10)
F 0.0 ± 0.00 (0/10) 0.2 ± 0.13 (2/10) 1.0 ± 0.33 (5/10)* 1.2 ± 0.28 (7/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.4 ± 0.16 (4/10)* 0.0 ± 0.00 (0/6) 0.8 ± 0.31 (4/6)# 0.0 ± 0.00 (0/9)
Nose level 2 Respiratory epithelium Reserve cell
hyperplasia
M 0.0 ± 0.00 (0/10) 0.6 ± 0.18 (5/9)** 2.9 ± 0.23 (10/10)*** 3.8 ± 0.13 (10/10)*** 0.2 ± 0.13 (2/10) 0.1 ± 0.10 (1/10) 0.2 ± 0.13 (2/10) 0.0 ± 0.00 (0/6) 0.8 ± 0.20 (4/5)## 0.1 ± 0.13 (1/8)
F 0.3 ± 0.15 (3/10) 0.7 ± 0.21 (6/10) 3.2 ± 0.13 (10/10)*** 4.4 ± 0.18 (9/9)*** 0.1 ± 0.10 (1/10) 0.2 ± 0.15 (2/9) 0.7 ± 0.26 (5/10) 0.0 ± 0.00 (0/6) 1.0 ± 0.26 (5/6)## 0.1 ± 0.10 (1/10)
Squamous epithelial
metaplasia
M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 1.2 ± 0.33 (7/10)** 2.2 ± 0.20 (10/10)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/8)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 1.1 ± 0.31 (7/10)** 2.8 ± 0.15 (9/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/10)
Olfactorepithelium Atrophy M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 2.0 ± 0.69 (5/9)** 4.5 ± 0.17 (10/10)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.1 ± 0.10 (1/10) 0.2 ± 0.17 (1/6) 3.0 ± 0.77 (4/5)# 0.5 ± 0.50 (1/8)
F 0.0 ± 0.00 (0/10) 0.4 ± 0.31 (2/10) 3.6 ± 0.22 (10/10)*** 4.9 ± 0.11 (9/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.7 ± 0.26 (5/10)* 0.0 ± 0.00 (0/6) 3.2 ± 0.17 (6/6)## 0.2 ± 0.20 (1/10)
Squamous epithelial
metaplasia
M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 1.0 ± 0.41 (4/9)* 2.1 ± 0.38 (8/10)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 1.2 ± 0.37 (4/5)# 0.1 ± 0.13 (1/8)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 2.6 ± 0.22 (10/10)*** 2.8 ± 0.40 (8/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.7 ± 0.33 (3/6) 0.0 ± 0.00 (0/10)
Lamina propria Loss of nerve bundles M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 1.6 ± 0.58 (5/9)** 4.3 ± 0.52 (9/10)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 4.0 ± 1.00 (4/5)## 0.6 ± 0.63 (1/8)
F 0.0 ± 0.00 (0/10) 0.3 ± 0.30 (1/10) 4.0 ± 0.52 (9/10)*** 5.0 ± 0.00 (9/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 4.8 ± 0.17 (6/6)## 0.3 ± 0.30 (1/10)
Mixed inﬂammatory
cell inﬁltrates
M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.2 ± 0.22 (1/9) 1.3 ± 0.21 (9/10)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.8 ± 0.20 (4/5)## 0.1 ± 0.13 (1/8)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.4 ± 0.22 (3/10) 1.8 ± 0.22 (9/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 1.2 ± 0.17 (6/6)## 0.0 ± 0.00 (0/10)
Nose level 3 Olfactory epithelium Atrophy M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.7 ± 0.47 (2/9) 4.0 ± 0.00 (10/10)*** 0.0 ± 0.00 (0/8) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 3.2 ± 0.80 (4/5)## 0.0 ± 0.00 (0/10)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 3.4 ± 0.43 (9/10)*** 4.0 ± 0.00 (9/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 3.2 ± 0.65 (5/6)## 0.0 ± 0.00 (0/10)
Squamous epithelial
metaplasia
M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.4 ± 0.29 (2/9) 3.1 ± 0.10 (10/10)*** 0.0 ± 0.00 (0/8) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 1.0 ± 0.32 (4/5)# 0.0 ± 0.00 (0/10)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 2.5 ± 0.34 (9/10)*** 3.0 ± 0.00 (9/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.8 ± 0.17 (5/6)## 0.0 ± 0.00 (0/10)
Lamina propria Loss of nerve bundles M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.4 ± 0.29 (2/9) 3.7 ± 0.21 (10/10)*** 0.0 ± 0.00 (0/8) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 3.2 ± 0.80 (4/5)## 0.0 ± 0.00 (0/10)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 3.4 ± 0.43 (9/10)*** 4.0 ± 0.00 (9/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 3.2 ± 0.65 (5/6)## 0.0 ± 0.00 (0/10)
Nose level 4 Olfactory epithelium Atrophy M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.2 ± 0.22 (1/9) 3.3 ± 0.40 (9/10)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.2 ± 0.20 (1/5) 0.0 ± 0.00 (0/10)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 2.4 ± 0.34 (9/9)*** 3.0 ± 0.29 (9/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.8 ± 0.31 (4/6)# 0.0 ± 0.00 (0/10)
Squamous epithelial
metaplasia
M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.1 ± 0.11 (1/9) 2.9 ± 0.35 (9/10)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/10)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 1.8 ± 0.43 (7/9)*** 2.0 ± 0.37 (8/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/10)
Lamina propria Loss of nerve bundles M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.2 ± 0.22 (1/9) 3.0 ± 0.37 (9/10)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/10)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 1.8 ± 0.49 (6/9)** 2.7 ± 0.37 (8/9)*** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/10)
Larynx Ventral depression Squamous epithelial
metaplasia
M 0.0 ± 0.00 (0/10) 2.1 ± 0.28 (10/10)*** 4.2 ± 0.33 (10/10)*** 4.3 ± 0.41 (8/8)*** 0.0 ± 0.00 (0/10) 0.3 ± 0.16 (2/8) 0.4 ± 0.24 (3/9) 0.0 ± 0.00 (0/6) 0.4 ± 0.24 (2/5) 0.0 ± 0.00 (0/10)
F 0.0 ± 0.00 (0/10) 4.1 ± 0.46 (10/10)*** 4.8 ± 0.13 (10/10)*** 3.9 ± 0.61 (8/9)*** 0.5 ± 0.50 (1/10) 0.0 ± 0.00 (0/9) 0.8 ± 0.42 (4/10)* 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/10)
Amount of
corniﬁcation
M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 2.8 ± 0.73 (7/10)** 3.1 ± 0.83 (6/8)** 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/8) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/10)
F 0.0 ± 0.00 (0/10) 3.3 ± 0.72 (8/10)*** 4.0 ± 0.67 (8/10)*** 3.3 ± 0.83 (6/9)** 0.5 ± 0.50 (1/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/10)
Lower medial region Hyperplasia M 0.3 ± 0.21 (2/10) 3.6 ± 0.18 (9/9)*** 4.1 ± 0.11 (9/9)*** 4.1 ± 0.13 (8/8)*** 1.6 ± 0.18 (9/9)** 2.3 ± 0.26 (10/10)*** 2.8 ± 0.15 (9/9)*** 0.5 ± 0.50 (1/6) 2.6 ± 0.51 (5/5)# 1.0 ± 0.17 (8/9)#
F 0.1 ± 0.11 (1/9) 4.1 ± 0.10 (10/10)*** 4.3 ± 0.15 (10/10)*** 4.5 ± 0.19 (8/8)*** 1.8 ± 0.43 (8/9)** 2.3 ± 0.26 (10/10)*** 3.2 ± 0.25 (10/10)*** 0.0 ± 0.00 (0/6) 3.2 ± 0.20 (5/5)## 0.5 ± 0.22 (4/10)
Amount of
corniﬁcation
M 0.0 ± 0.00 (0/10) 1.7 ± 0.55 (5/9)** 3.7 ± 0.24 (9/9)*** 3.4 ± 0.53 (7/8)*** 0.0 ± 0.00 (0/9) 0.4 ± 0.31 (2/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/6) 0.2 ± 0.20 (1/5) 0.0 ± 0.00 (0/9)
F 0.0 ± 0.00 (0/9) 3.0 ± 0.47 (9/10)*** 4.3 ± 0.21 (10/10)*** 4.6 ± 0.38 (8/8)*** 0.1 ± 0.11 (1/9) 0.0 ± 0.00 (0/10) 0.1 ± 0.10 (1/10) 0.0 ± 0.00 (0/6) 2.0 ± 0.71 (4/5)# 0.0 ± 0.00 (0/10)
Upper medial region Squamous epithelial
metaplasia
M 0.0 ± 0.00 (0/9) 1.9 ± 0.45 (7/9)** 3.9 ± 0.39 (9/9)*** 3.9 ± 0.30 (8/8)*** 0.2 ± 0.22 (1/9) 0.6 ± 0.40 (3/10) 1.2 ± 0.49 (5/9)* 0.0 ± 0.00 (0/6) 0.2 ± 0.20 (1/5) 0.3 ± 0.25 (1/8)
F 0.0 ± 0.00 (0/9) 3.5 ± 0.45 (9/10)*** 4.6 ± 0.16 (10/10)*** 4.9 ± 0.13 (8/8)*** 0.9 ± 0.51 (3/9) 0.9 ± 0.41 (5/10)* 1.4 ± 0.60 (5/10)* 0.0 ± 0.00 (0/6) 0.4 ± 0.40 (1/5) 0.0 ± 0.00 (0/10)
Amount of
corniﬁcation
M 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/9) 0.4 ± 0.29 (2/9) 1.1 ± 0.74 (2/8) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/8)
F 0.0 ± 0.00 (0/9) 0.5 ± 0.50 (1/10) 1.0 ± 0.56 (3/10) 3.9 ± 0.64 (7/8)*** 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.5 ± 0.50 (1/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/10)
Vocal folds, pseudostratiﬁed
epithelium
Squamous epithelial
metaplasia
M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/8) 0.4 ± 0.24 (3/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/8) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/10)
F 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/9) 0.6 ± 0.50 (2/8) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/9)
Vocal folds, squamous
epithelium
Hyperplasia M 0.1 ± 0.10 (1/10) 2.4 ± 0.34 (10/10)*** 3.8 ± 0.22 (9/9)*** 4.0 ± 0.00 (10/10)*** 0.7 ± 0.26 (5/10)* 1.1 ± 0.23 (8/10)** 1.4 ± 0.38 (7/9)** 0.8 ± 0.48 (2/4) 1.8 ± 0.49 (4/5) 0.9 ± 0.45 (4/9)
F 0.0 ± 0.00 (0/10) 3.2 ± 0.28 (9/9)*** 3.9 ± 0.10 (10/10)*** 3.5 ± 0.53 (7/8)*** 1.5 ± 0.50 (7/10)** 1.1 ± 0.38 (7/10)** 2.1 ± 0.38 (9/10)*** 0.0 ± 0.00 (0/6) 2.2 ± 0.58 (4/5)# 0.4 ± 0.22 (3/10)
Amount of
corniﬁcation
M 0.0 ± 0.00 (0/10) 1.2 ± 0.39 (6/10)** 2.4 ± 0.53 (8/9)*** 3.9 ± 0.31 (10/10)*** 0.0 ± 0.00 (0/10) 0.1 ± 0.10 (1/10) 0.4 ± 0.29 (2/9) 0.0 ± 0.00 (0/4) 0.0 ± 0.00 (0/5) 0.3 ± 0.33 (1/9)
F 0.0 ± 0.00 (0/10) 1.6 ± 0.50 (6/9)** 4.1 ± 0.23 (10/10)*** 3.9 ± 0.61 (7/8)*** 0.8 ± 0.51 (3/10) 0.3 ± 0.30 (1/10) 0.5 ± 0.27 (3/10) 0.0 ± 0.00 (0/6) 1.6 ± 0.40 (4/5)## 0.1 ± 0.10 (1/10)
Bifurcation Squamous epithelial
metaplasia
M 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/9) 0.1 ± 0.10 (1/10) 0.4 ± 0.16 (4/10)* 0.1 ± 0.10 (1/10) 0.0 ± 0.00 (0/9) 0.1 ± 0.10 (1/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/4) 0.0 ± 0.00 (0/9)
F 0.0 ± 0.00 (0/9) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/8) 0.8 ± 0.48 (3/6)* 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.1 ± 0.10 (1/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/10)
Goblet cell hyperplasia M 0.0 ± 0.00 (0/10) 0.2 ± 0.15 (2/9) 0.7 ± 0.26 (5/10)* 1.1 ± 0.23 (8/10)*** 0.0 ± 0.00 (0/10) 0.1 ± 0.10 (1/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/10)
F 0.1 ± 0.11 (1/9) 0.3 ± 0.21 (2/10) 0.1 ± 0.11 (1/9) 0.6 ± 0.38 (3/8) 0.2 ± 0.20 (1/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 0.2 ± 0.17 (1/6) 0.0 ± 0.00 (0/10)
Left lung Alveolar lumen Macrophages without
pigmentation
M 1.4 ± 0.22 (10/10) 2.0 ± 0.21 (10/10)* 3.1 ± 0.18 (10/10)*** 3.4 ± 0.16 (10/10)*** 0.8 ± 0.20 (7/10) 0.9 ± 0.31 (6/10) 1.4 ± 0.27 (9/10) 0.5 ± 0.22 (3/6) 1.0 ± 0.00 (5/5) 0.8 ± 0.25 (6/10)
F 0.7 ± 0.15 (7/10) 2.7 ± 0.15 (10/10)*** 2.8 ± 0.20 (10/10)*** 3.4 ± 0.18 (9/9)*** 0.9 ± 0.18 (8/10) 0.7 ± 0.21 (6/10) 1.5 ± 0.17 (10/10)** 0.8 ± 0.31 (4/6) 1.3 ± 0.21 (6/6) 0.5 ± 0.17 (5/10)
Macrophages with
pigmentation (yellow)
M 0.0 ± 0.00 (0/10) 0.9 ± 0.31 (5/10)* 2.7 ± 0.30 (10/10)*** 3.4 ± 0.22 (10/10)*** 0.1 ± 0.10 (1/10) 0.3 ± 0.21 (2/10) 0.7 ± 0.40 (3/10) 0.2 ± 0.17 (1/6) 1.4 ± 0.24 (5/5)## 0.2 ± 0.13 (2/10)
F 0.0 ± 0.00 (0/10) 1.5 ± 0.31 (8/10)*** 2.2 ± 0.29 (9/10)*** 3.6 ± 0.18 (9/9)*** 0.1 ± 0.10 (1/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/10) 0.0 ± 0.00 (0/6) 2.3 ± 0.21 (6/6)## 0.3 ± 0.15 (3/10)
Neutrophilic
granulocytes
M 0.6 ± 0.40 (3/10) 0.3 ± 0.15 (3/10) 1.0 ± 0.26 (7/10) 1.2 ± 0.20 (9/10)* 0.0 ± 0.00 (0/10) 0.4 ± 0.16 (4/10) 0.5 ± 0.27 (3/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/5) 0.0 ± 0.00 (0/10)
F 0.2 ± 0.13 (2/10) 0.6 ± 0.22 (5/10) 1.2 ± 0.25 (8/10)** 1.6 ± 0.18 (9/9)*** 0.2 ± 0.13 (2/10) 0.3 ± 0.30 (1/10) 0.1 ± 0.10 (1/10) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/6) 0.0 ± 0.00 (0/10)
Main bronchus Goblet cell hyperplasia M 0.5 ± 0.27 (3/8) 1.7 ± 0.40 (10/10)* 3.2 ± 0.36 (9/9)*** 4.8 ± 0.15 (9/9)*** 0.4 ± 0.44 (1/9) 0.8 ± 0.57 (2/9) 0.5 ± 0.19 (4/8) 0.0 ± 0.00 (0/5) 1.0 ± 0.45 (3/5) 0.3 ± 0.25 (1/8)
F 0.4 ± 0.22 (3/10) 2.1 ± 0.64 (7/10)* 3.2 ± 0.46 (9/9)*** 4.0 ± 0.24 (9/9)*** 0.8 ± 0.33 (5/10) 0.2 ± 0.13 (2/10) 0.8 ± 0.39 (5/10) 0.0 ± 0.00 (0/5) 0.8 ± 0.31 (4/6)# 0.0 ± 0.00 (0/10)
Histopathological evaluation was performed after 90-day exposure (90d) and 42-day recovery following a 90-day exposure period (90 þ 42d). Results represent mean score ±standard error; incidence and sample size are in
parentheses. Difference from sham group at 90d: Signiﬁcance: *p < 0.05; **p < 0.01; ***p < 0.001. Difference from sham group at 90 þ 42d: Signiﬁcance: #p < 0.05; ##p < 0.01; ###p < 0.001. Abbreviations: M, male; F, female.
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Most ﬁndings in non-respiratory tract organs were incidental,
did not reach statistical signiﬁcance in comparison to control
groups, and were considered normal background levels for Sprague
Dawley rats. Even though themeanmyeloid: erythroid cell ratios in
the bone marrow of the male 3R4F_23 and THS2.2_50 groups were
showing trend of increased compared with the sham group, the
mean ratio was not statistically signiﬁcant and did not differ be-
tween the 3R4F and THS2.2 groups; the ratios were within the
expected physiological range (data not shown). Lower relative
thymus weights were observed in the 3R4F- and THS2.2-exposed
groups relative to sham (Table 10). The organ weight effect was
correlated with mild to moderate thymus atrophy in the 3R4F- and
THS2.2-exposed groups (Table 14). In general, the magnitude of the
effect did not differ between the 3R4F- and THS2.2-exposed groups.
Higher relative adrenal gland weights, indicative of a stress
response (Coggins et al., 1989; Everds et al., 2013; Gaworski et al.,
2009), were observed in both the 3R4F- and THS2.2-exposed ani-
mals compared with the sham group; this ﬁnding was reversed at
the end of the post-exposure recovery period (Table 10). The rela-
tive weights of adrenal glands were similar between the 3R4F- and
THS2.2-exposed groups, with the exception of the incidental lower
right adrenal gland weights in THS2.2_23 males, compared with
the 3R4F_23 group (Table 11). No consistent exposure-related his-
topathological changes were observed in the adrenal glands (data
not shown). Also consistent with the stress response in exposed
rats, a reduction in relative spleen weights was seen in both the
3R4F- and THS2.2-exposed female groups relative to sham, which
was reversed in the post-exposure recovery groups. The relative
weights of the spleen did not differ between the THS2.2 and 3R4F
groups at the same nicotine exposure concentrations. Other than
reduced yellow pigmentation in the red pulp in the female 3R4F_8,
3R4F_15, THS2.2_23, and THS2.2_50 groups, no other statistically
signiﬁcant histopathological ﬁndings were found (Table 14). The
relative weights of the livers were higher in the male 3R4F_23 and
THS2.2_23 and THS2.2_50 groups when compared with the sham
group. The liver weights were higher in the female 3R4F_15 and
3R4F_23 groups and in all THS2.2 groups compared with the sham
(Table 10). In female rats, the relative liver weights were higher in
the THS2.2_50 group but not in the THS2.2_23 compared with the
3R4F_23 group (Table 11). An increase in the severity score and
incidence of cytoplasmic vacuolization was observed in the hepa-
tocytes of the THS2.2_23 and THS2.2_50 female groups compared
with the sham (Table 14). However, when compared with the 3R4F
groups, no concentration-dependent difference was found. Both
severity score and incidence of cytoplasmic vacuolization in the
liver reverted back to baseline levels after the 42 days’ recovery
period.
An aerosol-induced reduction in relative uterus weights was
seen in both the 3R4F- and THS2.2-exposed female groups, andwas
reversed in the post-exposure recovery groups (Table 10). The
relative uterus weights did not differ between the THS2.2 and 3R4F
groups at the same nicotine concentrations (Table 11). A lower level
of eosinophilic granulocytes in the stroma of the uterus was found
in the 3R4F_15, 3R4F_23, THS2.2_23, and THS2.2_50 groups, with
no differences observed between the test and reference groups. No
other structural changes to uterine cells were found (Table 14).
3.7. Transcriptomics
Gene expression changes in RNE and lung tissue of 3R4F- and
THS 2.2-exposed male rats after 90 days of exposure or after a 42-
day recovery period were compared with their respective sham
exposed group. The amplitude (expressed as negative log-fold
change) and statistical signiﬁcance of gene expression changes
are shown in volcano plots (Fig. 3).After 90 days of exposure, the number of differentially
expressed genes in the RNE and in the lung tissue increased with
increasing 3R4F smoke concentration in male rats, and to a lesser
extent in the THS 2.2-exposed rats. No differentially expressed
genes were detected above the applied threshold of false discovery
rate (FDR) corrected p-value < 0.05 in the RNE and lung tissues of
the THS2.2-exposed animals. After the 42-day recovery period, the
observed effects in male rats were generally lower than in the 90-
day exposure groups, with only a few differentially expressed genes
in the RNE and lung tissues of the 3R4F groups. However, it should
be noted that despite not reaching statistical signiﬁcance, some
genes showed high fold changes in expression in 3R4F_15 and
3R4F_23 post-exposure groups that were not seen in the THS2.2_50
post-exposure groups (see volcano plots in Fig. 3).
A heatmap was generated to obtain an overview of the overlap
of differentially expressed genes between the groups
(Supplementary Fig. 2). The visualization of the changes in tran-
scriptional proﬁles provided by a heatmap offers the advantage that
each gene which was signiﬁcantly differentially expressed in one
group could be compared with its fold change in the other groups.
The heatmap shows that differential gene expression (fold change)
in the RNE of male rats increased steeply with the highest 3R4F
concentration, whereas the differential gene expression in lung
tissue increased more gradually with increasing 3R4F concentra-
tion. In both tissues, the amplitude of change of the differentially
expressed genes was clearly lower in the THS2.2-exposed groups,
compared with the 3R4F-exposed groups. Even though THS2.2
exposure induced expression of some genes compared with the
sham group, the fold change in expression did not reach statistical
signiﬁcance.
To examine which biological processes were affected by 3R4F
and THS2.2 exposure in the RNE and in the lung tissue of male rats,
the previously described network models reﬂecting the biological
processes that are known to be perturbed by MS were used (Boue
et al., 2015; Gebel et al., 2013; Schlage et al., 2011; Westra et al.,
2011, 2013). The perturbation of those network models can be
qualitatively assessed and mathematically quantiﬁed (Martin et al.,
2014). As shown in Fig. 4, the affected biological processes in the
RNE follow a steep exposure concentration-dependent increase in
3R4F-exposed groups after 90 days of exposure. The star plots in
Fig. 4 show the biological processes scaled for their relative
contribution to the overall affected network. The main affected
biological processes in the 3R4F_23 group included the inﬂam-
matory processes, the cell fate processes, the tissue repair and
angiogenesis processes, and cell stress processes. Only minimal
network perturbation was detectable in the THS2.2-exposed
groups. After the 42-day recovery period, most of the affected
biological processes were still detectable in the 3R4F groups, even
though obvious attenuation of the affected biological processes was
observed, including the inﬂammatory and cell fate processes.
In the lung tissue, a strong effect on biological processes was
observed following exposure to 3R4F. The inﬂammatory processes
showed the greatest modiﬁcations in the 3R4F_23 group following
a 90-day exposure. Other major perturbed processes in the
3R4F_23 group included the cell fate processes, tissue repair and
angiogenesis, and cell stress processes (Fig. 4). In contrast, much
weaker network perturbations were evident following THS2.2
exposure, which mainly showed perturbation of the inﬂammatory
processes. The affected biological processes in the 90-day exposed
3R4F groups were also detectable after the 42-day recovery period.
The extent to which the inﬂammation processes were affected was
similar in the 3R4F post-exposure groups, compared with the 90-
day exposed group. The extent of the effect on other perturbed
networks was either small or none in the 3R4F post-exposure
groups, compared with the 90-day exposed group. In contrast,
E.T. Wong et al. / Regulatory Toxicology and Pharmacology 81 (2016) S59eS81 S75attenuation of the networks’ perturbation was observed in the
THS2.2 recovery groups. In summary, the transcriptomics analysis
further supports an overall reduced biological impact of THS2.2
exposure on the nasal epithelium and lung tissue compared with
3R4F.
4. Discussion
A 90-day inhalation study was conducted to compare the sub-
chronic inhalation toxicity in Sprague Dawley rats exposed to the
aerosol from the MRTP THS2.2 and the 3R4F reference cigarette.
Ninety-day inhalation studies conducted according to OECD Test
Guideline 413 are a commonly used approach to assess general
toxicity following inhalation exposure to MS from cigarettes or to
other aerosols (Moennikes et al., 2008; Piade et al., 2014; Terpstra
et al., 2003; Vanscheeuwijck et al., 2002). In this study, the
testing approach was extended to include an evaluation of molec-
ular endpoints to complement the classical methods of toxicolog-
ical assessment, as well as provide insights into the mechanistic
drivers for the changes observed (Kogel et al., 2014; Phillips et al.,
2015b, 2016).
The overall study mean nicotine concentrations, along with
reproducible PSD of the aerosols, indicate that the aerosol was
generated and delivered in a consistent manner to the inhalation
chambers with levels very close to the target concentrations. The
measured PSD for the test atmospheres (mass median aerodynamic
diameter (MMAD) ranging from 0.4 to 0.9 mm, see Table 1) was
below the speciﬁcation given in OECD TG 413 (MMAD ranging from
1 to 3 mm; geometric standard deviation (GSD) ranging from 1.5 to
3.0). The deposition fraction of the inhaled aerosol in the lung is
shown to increase as the particle size decreases from
1e5 mme0.5 mm MMAD (Kuehl et al., 2012). Hence, both aerosol
from THS2.2 and MS from 3R4F have a similar PSD and should
readily be deposited in the lungs and well taken up by the rats.
The maximum exposure concentrations selected for the 3R4F
and THS2.2 groups were 23 mg/l and 50 mg/l nicotine, respectively.
These concentrations were selected to detect the maximum
possible toxicities induced by the test and reference items. Based on
the formula described by Alexander et al. (Alexander et al., 2008),
the test atmosphere concentration of nicotine (50 mg/l) at 0.187 l/
min respiratory minute volume (value taken from current study)
for a 250 g male rat generated a delivered dose (DD) of nicotine
aerosol equivalent to (0.05 mg/l x 0.187 l/min x 360 min)/
0.25 kg ¼ 13.5 mg nicotine/kg body weight. An assumption based
on 100% retention of nicotine in the respiratory tract was made,
based on published data for humans (Baker and Dixon, 2006; Feng
et al., 2007; Gowadia and Dunn-Rankin, 2010). According to this
assumption and 1.39 mg nicotine per cigarette, and an average
human adult body weight of 60 kg, the human equivalence daily
dose is 13.5 mg/kg 60 kg¼ 810mg nicotine (or 583 cigarettes per
day). Alternatively, the human equivalent daily dose based on body
surface area (FDA, 2005) is 13.5 mg/kg/6.2  60 kg ¼ 131 mg
nicotine (or 94 cigarettes per day). Thus the applied exposure levels
were high and suitable for a toxicity study.
Exposure was monitored by frequent measurements of nicotine
concentrations at the breathing zone of the rats in the exposure
chambers, as well as other smoke constituents. Biomonitoring of
aerosol uptake was done by quantifying the metabolites of various
aerosol components in the urine of exposed rats. The recovery of
total nicotine metabolites was in direct correlation to the nicotine
test atmosphere concentrations of the same inhaled aerosol.
However, when compared with the 3R4F-exposed groups at the
same target nicotine concentrations, the uptake of aerosol con-
stituents was higher in the THS2.2-exposed rats, as evidenced in
the higher levels of total nicotine metabolites excreted in 24-hurine. The lower degree of irritation to the respiratory tract or-
gans and resultant higher respiratory minute volume in THS2.2-
exposed animals relative to 3R4F-exposed rats likely explains the
higher inhaled dose in the THS2.2-exposed groups. Measurement
of representative urinary metabolites of other aerosol components
indicated signiﬁcantly lower levels of harmful constituents such as
acrolein, NNK, benzene, and acrylonitrile in the aerosol from
THS2.2 compared with cigarettes, consistent with the reduced
HPHC present in the aerosol of THS2.2 (Schaller et al., submitted
(this issue)-a).
Exposure-related reduction in body weight was signiﬁcantly
less pronounced in THS2.2- than in 3R4F-exposed rats; this was
likely due to effects of harmful smoke constituents such as acrolein
in the 3R4F aerosol, affecting body weight gain (Feron et al., 1978).
Weight loss observed in the THS2.2 groups relative to shammay be
attributed to the effects of nicotine. Reduced body weights were
also observed in a nicotine-only inhalation study (Phillips et al.,
2015a), as well as in other studies where nicotine was adminis-
tered (Chowdhury, 1990; Ijomone et al., 2014; Seoane-Collazo et al.,
2014). The higher mean body weight and food consumption indi-
cated better general well-being and lower systemic toxicity in the
THS2.2-exposed animals, compared with the 3R4F-exposed ani-
mals. However, when compared with the sham group animals, the
aerosol-exposed males showed a reduction in body weight, while
aerosol-exposed females showed higher body weights compared
with their sham counterparts. The higher body weights in the
THS2.2-exposed female animals (relative to sham) were also
observed in a THS2.2 menthol study (Oviedo et al., submitted (this
issue)). While higher food consumption correlated with higher
body weights in the female THS2.2 groups, as also observed in the
THS2.2 menthol study (Oviedo et al., submitted (this issue)), an
increase in food consumption was not observed in a recent inha-
lation study involving nicotine pyruvate (Phillips et al., 2015a).
Furthermore, there have been a number of conﬂicting published
results pointing to the role of nicotine in appetite suppression
(Chen et al., 2007; Grunberg et al., 1984; Mineur et al., 2011;
Seoane-Collazo et al., 2014). Therefore more studies are needed to
identify whether these results are due to nicotine only or to other
constituents of the aerosol.
In comparison with MS from 3R4F, THS2.2 aerosol showed a
signiﬁcantly lower irritant effect on the respiratory tract. This was
evident from the relatively unaffected respiratory frequencies in
the THS2.2-exposed rats relative to sham. The histopathological
assessment of the respiratory tract organs, as well as lung inﬂam-
mation parameters (inﬂammatory cells and analytes in BALF), also
indicated a much lower biological activity of the THS2.2 MA than
the MS from 3R4F at equivalent nicotine concentrations. Aerosol-
related histopathological ﬁndings in the respiratory tract included
hyperplasia and squamous metaplasia in the epithelium of the
nasal cavity and larynx, accumulation of neutrophilic granulocytes
in the nasal cavity, and reserve cell and goblet cell hyperplasia at
the tracheal epithelium. At equivalent nicotine concentrations in
the test atmosphere, the incidence and severity of these lesions
were signiﬁcantly lower in the THS2.2-exposed rats. Lung inﬂam-
mation, as reﬂected by the accumulation of pigmented alveolar
macrophages and neutrophilic granulocytes, as well as the pres-
ence of pro-inﬂammatory and chemotactic cytokines in the bron-
choalveolar lavage ﬂuid, was signiﬁcantly lower in THS2.2- than in
3R4F-exposed groups.
The toxicity due to sub-chronic inhalation of the test atmo-
spheres was evaluated according to the recommendations stated in
the OECD Test Guideline 413 (OECD, 2009). Exposure-related
changes were not observed in the evaluated RBC parameters and
most of the non-respiratory tract organs and clinical chemistry
parameters. Inhalation exposure-induced responses, such as
Table 13
Statistical signiﬁcance difference in histopathological ﬁndings in the respiratory tract organs between animals exposed to aerosol from THS2.2 and cigarette smoke from 3R4F.
Localization Tissue type Observation Sex 90d 90 þ 42d
THS2.2_15
vs. 3R4F_15
THS2.2_23
vs. 3R4F_23
THS2.2_50
vs. 3R4F_23
THS2.2_50
vs. 3R4F_23
Nose level 1 Respiratory epithelium Reserve cell hyperplasia M Y** Y*** Y** Y*
F Y*** Y*** Y*** Y**
Squamous epithelial metaplasia M Y*** Y*** Y*** Y**
F Y*** Y*** Y** Y***
Amount of corniﬁcation M ¼ Y*** Y*** Y***
F Y** Y*** Y*** Y***
Loss of goblet cells (septum) M Y*** Y*** Y*** ¼
F Y*** Y*** Y** Y**
Neutrophilic granulocytes M Y* Y* Y* ¼
F Y* Y*** Y* Y**
Nose level 2 Respiratory epithelium Reserve cell hyperplasia M Y*** Y*** Y*** Y*
F Y*** Y*** Y*** Y**
Squamous epithelial metaplasia M Y** Y*** Y*** ¼
F Y** Y*** Y*** ¼
Olfactory epithelium Atrophy M Y** Y*** Y*** Y*
F Y*** Y*** Y*** Y***
Squamous epithelial metaplasia M Y* Y*** Y*** Y*
F Y*** Y*** Y*** Y*
Lamina propria Loss of nerve bundles M Y** Y*** Y*** Y*
F Y*** Y*** Y*** Y***
Mixed inﬂammatory cell inﬁltrates M ¼ Y*** Y*** Y*
F ¼ Y*** Y*** Y***
Nose level 3 Olfactory epithelium Atrophy M ¼ Y*** Y*** Y**
F Y*** Y*** Y*** Y***
Squamous epithelial metaplasia M ¼ Y*** Y*** Y**
F Y*** Y*** Y*** Y***
Lamina propria Loss of nerve bundles M ¼ Y*** Y*** Y**
F Y*** Y*** Y*** Y***
Nose level 4 Olfactory epithelium Atrophy M ¼ Y*** Y*** ¼
F Y*** Y*** Y*** Y**
Squamous epithelial metaplasia M ¼ Y*** Y*** ¼
F Y*** Y*** Y*** ¼
Lamina propria Loss of nerve bundles M ¼ Y*** Y*** ¼
F Y** Y*** Y*** ¼
Larynx Ventral depression Squamous epithelial metaplasia M Y*** Y*** Y*** Y*
F Y*** Y*** Y** ¼
Amount of corniﬁcation M Y** Y** Y** ¼
F Y** Y** Y** ¼
Lower medial region Hyperplasia M Y*** Y*** Y*** Y**
F Y*** Y*** Y** Y**
Amount of corniﬁcation M Y*** Y** Y*** ¼
F Y*** Y*** Y*** Y**
Upper medial region Squamous epithelial metaplasia M Y*** Y*** Y** ¼
F Y*** Y*** Y*** ¼
Amount of corniﬁcation M ¼ ¼ ¼ ¼
F ¼ Y*** Y** ¼
Vocal folds, pseudostratiﬁed epithelium Squamous epithelial metaplasia M ¼ ¼ ¼ ¼
F ¼ ¼ ¼ ¼
Vocal folds, squamous epithelium Hyperplasia M Y*** Y*** Y*** ¼
F Y** Y* Y* Y*
Amount of corniﬁcation M Y*** Y*** Y*** ¼
F Y** Y*** Y** Y**
Bifurcation Squamous epithelial metaplasia M ¼ Y* ¼ ¼
F ¼ Y* ¼ ¼
Goblet cell hyperplasia M Y* Y** Y*** ¼
F ¼ Y* Y* ¼
Left lung Alveolar lumen Macrophages without pigmentation M Y*** Y*** Y*** ¼
F Y*** Y*** Y*** Y*
Macrophages with pigmentation (yellow) M Y*** Y*** Y*** Y**
F Y*** Y*** Y*** Y***
Neutrophilic granulocytes M Y** Y* Y* ¼
F Y** Y** Y*** ¼
Main bronchus Goblet cell hyperplasia M Y** Y*** Y*** ¼
F Y** Y*** Y*** Y**
Difference between groups: Signiﬁcance: *p < 0.05; **p < 0.01; ***p < 0.001. Symbols, Y indicates response lower in THS2.2 relative to 3R4F; ¼indicates no difference. Ab-
breviations: M, male; F, female.
E.T. Wong et al. / Regulatory Toxicology and Pharmacology 81 (2016) S59eS81S76changes in differential leukocyte counts in blood, lower serum
cholesterol, and glucose levels, higher activities of liver-related
enzymes in serum, higher organ weights for liver and adrenalglands, cytoplasmic vacuolization in the liver (female), and reduced
thymus (male), spleen (female) and uterus weights were observed
in both 3R4F- and THS2.2-exposed rats. The extent of change for
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3R4F- and THS2.2-exposed groups at the same nicotine concen-
tration. Similar effects were observed in published data involving
nicotine-containing aerosols (Moennikes et al., 2008; Oviedo
et al., submitted (this issue); Piade et al., 2014; Terpstra et al.,
2003; Vanscheeuwijck et al., 2002; Werley et al., 2008), and in a
nicotine-only exposure study (Phillips et al., 2015a). Higher blood
neutrophil counts and lower blood lymphocyte counts, in com-
bination with the increase in the weights of adrenal glands and
decreased weights for thymus and spleen, and are likely due to
stress (Everds et al., 2013) and/or the effects of nicotine (Phillips
et al., 2015a). The fold change in lymphocyte counts, as well as
adrenal, thymus and spleen weights in the 3R4F- and THS2.2-
exposed groups are very similar to those seen with nicotine-
only or nicotine pyruvate exposures at matched nicotine con-
centrations, as reported in a 28-day inhalation study by Phillips
et al. (Phillips et al., 2015a), suggesting a dominant effect of
nicotine on these parameters. The fold change in neutrophil
counts is approximately 2e3 times higher in this study than in the
28-day nicotine-only inhalation study (Phillips et al., 2015a),
suggesting that additional factors, such as the length of the study,
the age of the animals, or residual HPHCs, can inﬂuence neutro-
phil counts. The decrease in serum cholesterol and glucose levels
was also observed in our nicotine pyruvate 28-day inhalation
study (Phillips et al., 2015a) and in other inhalation and nicotine
administration studies (Latha et al., 1988; Seoane-Collazo et al.,
2014; Vu et al., 2014), thereby supporting the hypothesis that
chronic nicotine administration affects glucose and lipid meta-
bolism. The increased levels of activity of alkaline phosphatase
and alanine aminotransferase in serum and liver weights seen in
this study were very similarly observed in the 28-day inhalation
study involving nicotine pyruvate (Phillips et al., 2015a), sug-
gesting a dominant role for nicotine amongst the many compo-
nents of cigarette MS and THS2.2 aerosol in regulating these
processes. The underlying changes in lipid peroxidation in the
liver, as observed in response to cigaretteMS exposure (Watanabe
et al., 1995) and nicotine administration (Kalpana and Menon,
2004a, 2004b), may contribute to changes in enzymatic activ-
ities in the liver. An increase in glycogen content in the liver, as
reﬂected by periodic acid-Schiff (PAS)-positive granules (with and
without diastase treatment) in the livers of nicotine-exposed rats
is also in alignment with proposed metabolic activity changes in
the livers of nicotine-exposed rats (Phillips et al., 2015a). A higher
incidence of cytoplasmic vacuolization in the livers of female
THS2.2-exposed rats is possibly related to glycogen content in the
liver, and points to a role for nicotine in its regulation. Lastly,
lowered uterus weights (measured in the 3R4F MS- and THS2.2
aerosol-exposed rats) have also been reported in nicotine-only
administration studies (Iranloye and Bolarinwa, 2009; Patil
et al., 1999). The published literature indicates that nicotine may
exert an effect on rodent ovarian function (Blackburn et al., 1994),
which may explain the inﬂuence of exposure on uterus weights.
Of the 3R4F- and THS2.2-induced changes observed in this
study, the lower levels of serum albumin, total protein, and tri-
glycerides were not observed in the nicotine-only 28-day inha-
lation study (Phillips et al., 2015a). Reduced protein synthesis by
the liver in response to cigarette MS is a possible mechanism to
reduce serum albumin and total protein concentrations (Sershen
et al., 1981). To address whether chronic exposure to nicotine or
other aerosol components may be the cause for lower levels of
serum albumin would require further testing of total protein and
triglycerides. The inﬂuence of aerosol from cigarettes or nicotine
on decreasing serum triglyceride levels is likely multi-factorial,
possibly due to a reduction in nutritional status (food consump-
tion) and/or changes in lipid metabolism in response to cigarette
Fig. 3. Effects of 3R4F and THS2.2 exposure on the respiratory nasal epithelium (RNE) and lung transcriptome in male rats. For each gene, the gene expression change,
calculated as [log2(fold change)], is plotted on the x-axis and the statistical signiﬁcance, proportional to the [log10(adjusted p-value FDR)], was plotted on the y-axis. Yellow and
light blue dots indicate genes that were statistically signiﬁcantly up- or down-regulated, respectively, compared with sham exposed groups. The horizontal line represents statistical
signiﬁcance [log10(0.05)].The left side RNE and right lung lobes were analyzed following a 90-day exposure and 42-day post-exposure period. FDR, false discovery rate.
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2014; Winders and Grunberg, 1990). The effect of the reduction inFig. 4. Star plots showing relative network-level biological impact in the respiratory na
level biological impact for each exposure group was compared with the sham groups after
animals. The surface area of each segment is proportional to the contribution of each netw
sum of surface area for each exposure group is shown relative to the perturbation in the sserum albumin and total protein concentrations measured is likely
to beminimal, as these changes fall within the normal physiologicalsal epithelium (RNE) and lung tissues for all exposure groups. The relative network-
a 90-day exposure and following a 42-day recovery period in RNE and lungs of male
ork perturbation (shown as percentage in the labels) within each exposure group. The
ham group.
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concentrations of triglycerides and the comparisonwith the normal
physiological ranges in rats (Seibel et al., 2010) are complicated by
the fact that the animals were not diet-restricted prior to blood
collection and analysis. In summary, the toxicological changes
observed in the respiratory tract organs of the THS2.2 MA-exposed
rats were much less pronounced than in 3R4F MS-exposed rats. No
additional changes was trigged by THS2.2 comparedwith cigarettes
andmost observed changes are likely a reﬂection of the response to
nicotine exposure.
The systems toxicology-based assessment using transcriptomics
analysis further supports an overall reduced biological impact of
THS2.2 exposure on the RNE and the lung tissue when compared
with 3R4F exposure. The number of differentially expressed genes
was markedly lower in THS2.2-exposed animals, compared with
3R4F-exposed animals. The overall lower biological effect is
consistent with the histopathological evaluation and BALF analysis
of the THS2.2-exposed animals. Additionally, the use of gene
expression analysis in sub-acute toxicity testing can potentially
provide information on the toxicity mechanisms. The network-
based approach that was performed relies on the fold change of
the differentially expressed genes, and is a threshold-free method.
As a network-based approach integrates many genes in a single
network, it has higher statistical power than a gene-level analysis.
Consistent with published data, the network model-based analysis
used in this study suggested that inﬂammatory processes were the
major affected biological processes in the RNE and lungs of the
3R4F-exposed groups (Boue et al., 2013; Kogel et al., 2014; Phillips
et al., 2015b). Histologically, the presence of increased neutrophilic
granulocytes on the respiratory epithelium of nose level 1, the
ﬁndings of increased macrophages and neutrophilic granulocytes
in the alveolar lumen of the lungs, and increased levels of neutro-
phils, eosinophils, and inﬂammatory mediators in BALF, all corre-
lated well with the increased perturbation of the inﬂammatory
processes network in 3R4F-exposed animals. In contrast, the in-
ﬂammatory processes were much less affected in THS2.2-exposed
groups relative to the 3R4F-exposed groups; this ﬁnding is
consistent with the low level of accumulation of immune cells in
the respiratory tissues (nose and lungs) and inﬂammatory cyto-
kines in the BALF. Additionally, other molecular networks were
minimally affected in the RNE and lung tissues of THS2.2-exposed
animals, compared with 3R4F-exposed animals. After a 42-day
recovery, the inﬂammatory processes network was still detect-
able in the lungs of 3R4F-exposed animals, correlating with the
persistence of immune cells and inﬂammatory cytokines in the
BALF. Similarly, other molecular networks remained perturbed in
the 3R4F recovery groups, suggesting repair and long lasting post-
inhalation effect of MS on critical biological processes. In contrast,
amplitudes of minimally affected molecular networks in the
THS2.2- exposed animals were negligible in RNE and lungs of re-
covery animals.
In conclusion, the data indicated that the MA from THS2.2 did
not cause additional toxicity compared with MS from the 3R4F
cigarette, while the toxicity to respiratory tract organs in THS2.2-
exposed animals was much lower than in rats exposed to 3R4F.
Following exposure to THS2.2, most of the responses were
considerably reduced in comparison to 3R4F. Where ﬁndings were
similar between the 2 products, the responses were similar to ef-
fects caused by nicotine-alone exposure at comparable test atmo-
sphere concentrations.
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